Nuclear protein targeting engineered deubiquitinating enzymes and methods of use thereof
Patent Information
- Application Number
- JP2023527977
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-06
- Filing Date
- 2021-11-05
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for genetic diseases associated with decreased expression or stability of functional nuclear proteins are inadequate, particularly for haploinsufficiency diseases caused by loss-of-function mutations, as they primarily focus on symptom management rather than curative solutions.
Development of engineered deubiquitinating enzymes (enDubs) with a targeting moiety that specifically binds to nuclear proteins, combined with a catalytic domain to deubiquitinate these proteins, thereby increasing their expression and stability.
The engineered fusion proteins effectively target and enhance the expression and stability of nuclear proteins, providing a potential curative treatment for genetic diseases by reversing the effects of ubiquitination and degradation.
Smart Images

Figure 2022099025000001 
Figure 2022099025000002
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 63 / 110,616, filed November 6, 2020, the entire disclosure of which is incorporated herein by reference.
[0002] The present disclosure relates to fusion proteins comprising an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or variant thereof; and a targeting domain comprising a moiety that specifically binds to a target nuclear protein. The disclosure further relates to therapeutic methods using the same. [Background technology]
[0003] A subset of genetic diseases is associated with a decrease in the expression level or stability of functional nuclear proteins. For example, haploinsufficiency genetic diseases are caused by the presence of a single copy of a wild-type allele heterozygously combined with a loss-of-function variant allele, and the level of expressed functional protein is insufficient to produce a typical phenotype. Haploinsufficiency can result from de novo or inherited loss-of-function mutations in the variant allele, resulting in little or no functional protein being produced. Despite recent advances in gene therapy, there is still no cure for these diseases, and treatment typically focuses on symptom management. Therefore, new treatments are needed for diseases associated with a decrease in the expression or stability of functional nuclear proteins, such as genetic diseases. Summary of the Invention
[0004] In particular, the present invention provides an engineered deubiquitinase (enDub) comprising a targeting moiety that specifically binds to a nuclear target protein and a catalytic domain of a deubiquitinase. The targeting moiety directs the catalytic domain of the deubiquitinase to the specific target nuclear protein for deubiquitination. The fusion proteins described herein are particularly useful in methods for treating genetic diseases, particularly genetic diseases associated with or caused by reduced expression or stability of specific nuclear proteins.
[0005] In one aspect, provided herein is a fusion protein comprising: an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof; and a targeting domain comprising a targeting moiety that specifically binds to a nuclear protein.
[0006] In some embodiments, the deubiquitinating enzyme is a cysteine protease or a metalloprotease.
[0007] In some embodiments, the deubiquitinating enzyme is a cysteine protease, hi some embodiments, the cysteine protease is a ubiquitin-specific protease (USP), a ubiquitin C-terminal hydrolase (UCH), a Machado-Josephine domain protease (MJD), an ovarian tumor protease (OTU), a MINDY protease, or a ZUFSP protease.
[0008] In some embodiments, the cysteine protease is a USP, which may be USP1, USP2, USP3, USP4, USP5, USP6, USP7, USP8, USP9X, USP9Y, USP10, USP11, USP12, USP13, USP14, USP15, USP16, USP17, USP17L2, USP17L3, USP17L4, USP17L5, USP17L7, USP17L8, USP18, USP 19, USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27X, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, or USP46.
[0009] In some embodiments, the cysteine protease is UCH. In some embodiments, the UCH is BAP1, UCHL1, UCHL3, or UCHL5.
[0010] In some embodiments, the cysteine protease is MJD. In some embodiments, the MJD is ATXN3 or ATXN3L.
[0011] In some embodiments, the cysteine protease is an OTU. In some embodiments, the OTU is OTUB1 or OTUB2.
[0012] In some embodiments, the cysteine protease is MINDY. In some embodiments, MINDY is MINDY1, MINDY2, MINDY3, or MINDY4.
[0013] In some embodiments, the cysteine protease is ZUFSP. In some embodiments, the ZUFSP is ZUP1.
[0014] In some embodiments, the deubiquitinating enzyme is a metalloprotease. In some embodiments, the metalloprotease is a Jab1 / Mov34 / Mpr1 Pad1 N-terminal+(MPN+) (JAMM) domain protease.
[0015] In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 1-112.
[0016] In some embodiments, the catalytic domain comprises a catalytic domain derived from a deubiquitinating enzyme that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 1-112.
[0017] In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 113-220 or 423.
[0018] In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:423.
[0019] In some embodiments, the moiety that specifically binds to a nucleoprotein comprises an antibody, or a functional fragment or functional variant thereof. In some embodiments, the antibody, or functional fragment or functional variant thereof comprises a full-length antibody, a single-chain variable fragment (scFv), scFv2, scFv-Fc, Fab, Fab', F(ab')2, F(v), VHH, or (VHH)2. In some embodiments, the antibody, or functional fragment or functional variant thereof comprises a VHH or (VHH)2.
[0020] In some embodiments, the nuclear protein is a transcription factor. In some embodiments, the nuclear protein is selected from the group consisting of chromodomain-helicase-DNA binding protein 2 (CHD2), arginine-glutamic acid dipeptide repeat protein (RERE), cyclin-dependent kinase-like 5 (CDKL5), methyl-CpG binding protein 2 (MECP2), histone-lysine N-methyltransferase 2D (KMT2D), histone-lysine N-methyltransferase SETD5 (SETD5), zinc finger E-box-binding homeobox 2 (ZEB2), calmodulin-binding transcription activator 1 (CAMTA1), regulator of synaptic function FMR1 (FMR1), pre-mRNA-processing-splicing factor 8 (PRPF8), retinoic acid-inducible protein 1 (RAI1), CREB-binding protein (CREBBP), neurofibromin (NF1), and histone-lysine N-methyltransferase 2A (KMT2A), chromodomain-helicase-DNA binding protein Protein 4 (CHD4), H3 lysine-36-specific histone-lysine N-methyltransferase (NSD1), RNA polymerase II transcription mediator subunit 13-like (MED13L), maintenance of chromosome structure protein 1A (SMC1A), high-potency global transcriptional activator SNF2L2 (SMARCA2), AT-rich interacting domain-containing protein 1B (ARID1B), pogo transposable element with ZNF domain (POGZ), histone acetyltransferase KAT6B (KAT6B), AT-hook DNA-binding motif-containing protein 1 (AHDC1), histone acetyltransferase p300 (EP300), IQ motif and SEC7 domain-containing protein 2 (IQSEC2), transcription factor 20 (TCF20), putative polycomb group protein ASXL3 (ASXL3), histone acetyltransferase KAT6A (KAT6A), small nuclear ribonucleoprotein G (SNRPG), U6 The snRNA-associated Sm-like protein LSm2 (LSM2), or nuclear protein 2 (NUPR2).
[0021] In some embodiments, the nuclear protein is a transcription factor. In some embodiments, the nuclear protein is selected from the group consisting of chromodomain-helicase-DNA binding protein 2 (CHD2), arginine-glutamic acid dipeptide repeat protein (RERE), cyclin-dependent kinase-like 5 (CDKL5), methyl-CpG binding protein 2 (MECP2), histone-lysine N-methyltransferase 2D (KMT2D), histone-lysine N-methyltransferase SETD5 (SETD5), zinc finger E-box-binding homeobox 2 (ZEB2), calmodulin-binding transcription activator 1 (CAMTA1), regulator of synaptic function FMR1 (FMR1), pre-mRNA-processing-splicing factor 8 (PRPF8), retinoic acid-inducible protein 1 (RAI1), CREB-binding protein (CREBBP), neurofibromin (NF1), and histone-lysine N-methyltransferase 2A (KMT2A), chromodomain-helicase These proteins are histone-DNA binding protein 4 (CHD4), H3 lysine-36-specific histone-lysine N-methyltransferase (NSD1), RNA polymerase II transcription mediator subunit 13-like (MED13L), chromosome structural maintenance protein 1A (SMC1A), high-potency global transcriptional activator SNF2L2 (SMARCA2), AT-rich interacting domain-containing protein 1B (ARID1B), pogo transposable element with ZNF domain (POGZ), histone acetyltransferase KAT6B (KAT6B), AT-hook DNA-binding motif-containing protein 1 (AHDC1), histone acetyltransferase p300 (EP300), IQ motif and SEC7 domain-containing protein 2 (IQSEC2), transcription factor 20 (TCF20), putative Polycomb group protein ASXL3 (ASXL3), and histone acetyltransferase KAT6A (KAT6A).
[0022] In some embodiments, the nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 221-248 or 424-426.
[0023] In some embodiments, the effector domain is operably linked directly to the targeting domain. In some embodiments, the effector domain is operably linked indirectly to the targeting domain. In some embodiments, the effector domain is operably linked indirectly to the targeting domain via a peptide linker. In some embodiments, the effector domain is indirectly fused to the targeting domain via a peptide linker of sufficient length to allow the effector domain and the targeting domain to simultaneously bind to their respective target proteins. In some embodiments, the peptide linker comprises the amino acid sequence of any one of SEQ ID NOs: 427-436 or 249-367, or the amino acid sequence of any one of SEQ ID NOs: 427-436 or 249-367 containing one, two, or three amino acid modifications. In some embodiments, the peptide linker comprises the amino acid sequence of any one of SEQ ID NOs: 427-436, or the amino acid sequence of any one of SEQ ID NOs: 427-436 containing one, two, or three amino acid modifications.
[0024] In some embodiments, the effector domain is operably linked, either directly or indirectly, to the C-terminus of the targeting domain. In some embodiments, the effector moiety is operably linked, either directly or indirectly, to the N-terminus of the targeting domain.
[0025] In some embodiments, the fusion protein further comprises a nuclear localization signal (NLS). In some embodiments, the NLS is at the N-terminus of the fusion protein. In some embodiments, the NLS comprises the amino acid sequence of any one of SEQ ID NOs: 249-367.
[0026] In one aspect, the present invention provides a nucleic acid molecule that encodes the fusion protein described herein.In some embodiments, the nucleic acid molecule is a DNA molecule.In some embodiments, the nucleic acid molecule is an RNA molecule.
[0027] In one aspect, provided herein is a vector comprising a nucleic acid molecule described herein (e.g., a nucleic acid molecule encoding a fusion protein described herein). In some embodiments, the vector is a plasmid or a viral vector.
[0028] In one aspect, provided herein is a viral particle comprising a nucleic acid molecule described herein (e.g., a nucleic acid molecule encoding a fusion protein described herein).
[0029] In one aspect, provided herein is an in vitro cell or cell population comprising a fusion protein described herein, a nucleic acid molecule described herein, or a vector described herein.
[0030] In one aspect, provided herein is a pharmaceutical composition comprising a fusion protein described herein, a nucleic acid described herein, a vector described herein, or a viral particle described herein, and an excipient.
[0031] In one aspect, provided herein is a method of producing a fusion protein described herein, comprising introducing into a cell or cell population in vitro a nucleic acid molecule described herein, a vector described herein, or a viral particle described herein; culturing the cell or cell population in a culture medium under conditions suitable for expression of the fusion protein; isolating the fusion protein from the culture medium, and optionally purifying the fusion protein.
[0032] In one aspect, provided herein is a method of treating or preventing a disease in a subject, comprising administering to a subject in need thereof a fusion protein described herein, a nucleic acid molecule described herein, a vector described herein, a viral particle described herein, or a pharmaceutical composition described herein. In some embodiments, the subject is a human.
[0033] In some embodiments, the disease is associated with decreased expression of a functional version of a nuclear protein compared to non-diseased controls. In some embodiments, the disease is associated with decreased stability of a functional version of a nuclear protein compared to non-diseased controls. In some embodiments, the disease is associated with increased ubiquitination of a nuclear protein compared to non-diseased controls. In some embodiments, the disease is associated with increased ubiquitination and degradation of a nuclear protein compared to non-diseased controls. In some embodiments, the disease is a genetic disease.
[0034] In some embodiments, the disease is CHD2 encephalopathy, CDKL5 deficiency disorder, SETD5 syndrome, CAMTA1 syndrome, early infantile epileptic encephalopathy type 2, childhood-onset epileptic encephalopathy, 1p36 deletion syndrome, Rett syndrome, Kabuki syndrome 1, mental retardation autosomal dominant 23, Mowat-Wilson syndrome, cerebellar ataxia, fragile X syndrome, retinitis pigmentosa 13, Smith-Maginis syndrome, Rubinstein-Taybi syndrome, neurofibromatosis (e.g., type 1), Wilson syndrome, These disorders include: Dedemann-Steiner syndrome, Sifrim-Hitz-Weiss syndrome, Sotos syndrome, MED13L syndrome, SMC1A syndrome, Nicolaides-Baraitser syndrome, ARID1B-related disorders, White-Sutton syndrome, KAT6B disorders, Shea-Gibbs syndrome, Menke-Hennekam syndrome 2, IQSEC2-related disorders, TCF20-related disorders, Bainbridge-Lopers syndrome, or KATA6 syndrome.
[0035] In some embodiments, the target nuclear protein is CHD2 and the disease is childhood-onset epileptic encephalopathy; the target nuclear protein is CHD2 and the disease is CHD2 encephalopathy; the target nuclear protein is RERE and the disease is 1p36 deletion syndrome; the target nuclear protein is CDKL5 and the disease is early infantile epileptic encephalopathy (e.g., type 2); the target nuclear protein is CDKL5 and the disease is CDKL5 deficiency disorder; the target nuclear protein is MECP2 and the disease is Rett syndrome; the target nuclear protein is KMT2D and the disease is Kabuki syndrome 1; The target nuclear protein is SETD5, and the disease is mental retardation autosomal dominant 23; the target nuclear protein is ZEB2, and the disease is Mowat-Wilson syndrome; the target nuclear protein is KMT2A, and the disease is Wiedemann-Steiner syndrome; the target nuclear protein is CHD4, and the disease is Schifflim-Hitz-Weiss syndrome; the target nuclear protein is NSD1, and the disease is Sotos syndrome; the target nuclear protein is SMC1A, and the disease is SMC1A syndrome; the target nuclear protein is SMARCA2, and the disease is Nicolaides-Baraits syndrome. the target nuclear protein is ARID1B and the disease is an ARID1B-associated disorder; the target nuclear protein is POGZ and the disease is White-Sutton syndrome; the target nuclear protein is KAT6B and the disease is a KAT6B disorder; the target nuclear protein is AHDC1 and the genetic disease is Shea-Gibbs syndrome; the target nuclear protein is EP300 and the disease is Menke-Hennekam syndrome 2; the target nuclear protein is IQSEC2 and the disease is an IQSEC2-associated disorder; the target nuclear protein is TCF20 and the disease is TCF20 The target nuclear protein is ASXL3 and the disease is Bainbridge-Lopers syndrome; the target nuclear protein is KAT6A and the disease is KATA6 syndrome; the target nuclear protein is MED13L and the disease is MED13L syndrome; the target nuclear protein is CAMTA1 and the disease is CAMTA1 syndrome; the target nuclear protein is FMR1 and the disease is Fragile X syndrome; the target nuclear protein is PRPF8 and the disease is Retinitis Pigmentosa 13; the target nuclear protein is RAI1 and the disease is Smith-Maginnis syndrome;The target nuclear protein is CREBBP and the disease is Rubinstein-Taybi syndrome; or the target nuclear protein is NF1 and the disease is neurofibromatosis (e.g., type 1);
[0036] In some embodiments, the disease is a haploinsufficiency disease. In some embodiments, the haploinsufficiency disease is selected from the group consisting of early infantile epileptic encephalopathy type 2, childhood-onset epileptic encephalopathy, 1p36 deletion syndrome, Rett syndrome, mental retardation autosomal dominant 23, Mowat-Wilson syndrome, cerebellar ataxia, Smith-Maginis syndrome, or neurofibromatosis (e.g., type 1).
[0037] In some embodiments, the fusion protein is administered at a therapeutically effective dose. In some embodiments, the fusion protein is administered systemically or locally. In some embodiments, the fusion protein is administered intravenously, subcutaneously, or intramuscularly.
[0038] In one aspect, provided herein are fusion proteins described herein, polynucleotides described herein, DNA described herein, RNA described herein, vectors described herein, viral particles described herein, and pharmaceutical compositions described herein for use as pharmaceuticals.
[0039] In one aspect, provided herein are fusion proteins described herein, polynucleotides described herein, DNA described herein, RNA described herein, vectors described herein, viral particles described herein, and pharmaceutical compositions described herein for use in treating or suppressing a genetic disorder.
[0040] In one aspect, provided herein is a fusion protein comprising: (a) an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof; and (b) a targeting domain comprising a targeting moiety that specifically binds to a nuclear protein.
[0041] In some embodiments, the deubiquitinating enzyme is a cysteine protease or a metalloprotease.
[0042] In some embodiments, the deubiquitinating enzyme is a cysteine protease, hi some embodiments, the cysteine protease is a ubiquitin-specific protease (USP), a ubiquitin C-terminal hydrolase (UCH), a Machado-Josephine domain protease (MJD), an ovarian tumor protease (OTU), a MINDY protease, or a ZUFSP protease.
[0043] In some embodiments, the cysteine protease is a USP, which may be USP1, USP2, USP3, USP4, USP5, USP6, USP7, USP8, USP9X, USP9Y, USP10, USP11, USP12, USP13, USP14, USP15, USP16, USP17, USP17L2, USP17L3, USP17L4, USP17L5, USP17L7, USP17L8, USP18, USP19, USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, USP46, USP47, USP48, USP49, USP49L50, USP49L60, USP49L71, USP49L82, USP49L91, USP49L10, USP49L11, USP49L12, USP49L13, USP49L14, USP49L15, USP49L16, USP49L17, USP49L18, USP49L19, USP40L19, USP41L10, USP41L11, USP41L12, USP41L13, USP41L14, USP41L15, USP41L16, USP41L17, USP41L18, USP41L19 USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27X, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, and USP46.
[0044] In some embodiments, the cysteine protease is a UCH. In some embodiments, the UCH is selected from the group consisting of BAP1, UCHL1, UCHL3, and UCHL5.
[0045] In some embodiments, the cysteine protease is MJD. In some embodiments, the MJD is selected from the group consisting of ATXN3 and ATXN3L.
[0046] In some embodiments, the cysteine protease is an OTU. In some embodiments, the OTU is selected from the group consisting of OTUB1 and OTUB2.
[0047] In some embodiments, the cysteine protease is MINDY. In some embodiments, MINDY is selected from the group consisting of MINDY1, MINDY2, MINDY3, and MINDY4.
[0048] In some embodiments, the cysteine protease is ZUFSP. In some embodiments, the ZUFSP is ZUP1. In some embodiments, the deubiquitinating enzyme is a metalloprotease. In some embodiments, the metalloprotease is a Jab1 / Mov34 / Mpr1 Pad1 N-terminal + (MPN +) (JAMM) domain protease.
[0049] In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 1-112.
[0050] In some embodiments, the catalytic domain comprises a catalytic domain derived from a deubiquitinating enzyme that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 1-112.
[0051] In some embodiments, the catalytic domain comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 113-220.
[0052] In some embodiments, the moiety that specifically binds to a nucleoprotein comprises an antibody, or a functional fragment or functional variant thereof. In some embodiments, the antibody, or functional fragment or functional variant thereof comprises a full-length antibody, a single-chain variable fragment (scFv), scFv2, scFv-Fc, Fab, Fab', F(ab')2, F(v), or VHH. In some embodiments, the antibody, or functional fragment or functional variant thereof comprises a VHH.
[0053] In some embodiments, the nuclear protein is a transcription factor.
[0054] In some embodiments, the nuclear protein is selected from the group consisting of chromodomain-helicase-DNA binding protein 2 (CHD2), arginine-glutamic acid dipeptide repeat protein (RERE), cyclin-dependent kinase-like 5 (CDKL5), methyl-CpG binding protein 2 (MECP2), histone-lysine N-methyltransferase 2D (KMT2D), histone-lysine N-methyltransferase SETD5 (SETD5), zinc finger E-box-binding homeobox 2 (ZEB2), calmodulin-binding transcription activator 1 (CAMTA1), regulator of synaptic function FMR1 (FMR1), pre-mRNA-processing-splicing factor 8 (PRPF8), retinoic acid-inducible protein 1 (RAI1), CREB-binding protein (CREBBP), neurofibromin (NF1), and histone-lysine N-methyltransferase 2A (KMT2A), ...). A-binding protein 4 (CHD4), H3 lysine-36-specific histone-lysine N-methyltransferase (NSD1), RNA polymerase II transcription mediator subunit 13-like (MED13L), chromosome structural maintenance protein 1A (SMC1A), high-potency global transcriptional activator SNF2L2 (SMARCA2), AT-rich interacting domain-containing protein 1B (ARID1B), pogo transposable element with ZNF domain (POGZ), histone acetyltransferase KAT6B (KAT6B), AT-hook DNA-binding motif-containing protein 1 (AHDC1), histone acetyltransferase p300 (EP300), IQ motif and SEC7 domain-containing protein 2 (IQSEC2), transcription factor 20 (TCF20), putative polycomb group protein ASXL3 (ASXL3), and histone acetyltransferase KAT6A (KAT6A).
[0055] In some embodiments, the nucleoprotein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 221-248.
[0056] In some embodiments, the effector domain is directly fused with the targeting domain. In some embodiments, the effector domain is indirectly fused with the targeting domain. In some embodiments, the effector domain is indirectly fused with the targeting domain via a peptide linker. In some embodiments, the effector domain is indirectly fused with the targeting domain via a peptide linker of sufficient length to allow the effector domain and the targeting domain to simultaneously bind to their respective target proteins.
[0057] In some embodiments, the effector domain is fused to the C-terminus of the targeting domain. In some embodiments, the effector moiety is fused to the N-terminus of the targeting domain.
[0058] In some embodiments, the fusion protein further comprises a nuclear localization signal (NLS). In some embodiments, the NLS is at the N-terminus of the fusion protein.
[0059] In one aspect, the present invention provides a nucleic acid molecule that encodes the fusion protein described herein.In some embodiments, the nucleic acid molecule is a DNA molecule.In some embodiments, the nucleic acid molecule is an RNA molecule.
[0060] In one aspect, provided herein is a vector comprising a nucleic acid molecule described herein. In some embodiments, the vector is a plasmid or a viral vector.
[0061] In one aspect, provided herein is a viral particle comprising a nucleic acid described herein.
[0062] In one aspect, described herein is an in vitro cell or cell population comprising a fusion protein described herein, a nucleic acid molecule described herein, or a vector described herein.
[0063] In one aspect, provided herein is a pharmaceutical composition comprising a fusion protein described herein, a nucleic acid molecule described herein, a vector described herein, or a viral particle described herein, and an excipient.
[0064] In one aspect, provided herein is a method of producing a fusion protein described herein, comprising: (a) introducing into a cell or cell population in vitro a nucleic acid described herein, a vector described herein, or a viral particle described herein; (b) culturing the cell or cell population in a culture medium under conditions suitable for expression of the fusion protein; (c) isolating the fusion protein from the culture medium; and (d) optionally purifying the fusion protein.
[0065] In one aspect, provided herein is a method of treating a disease in a subject comprising administering to a subject in need thereof a fusion protein described herein, a nucleic acid described herein, a vector described herein, or a viral particle described herein, or a pharmaceutical composition described herein.
[0066] In some embodiments, the subject is a human.
[0067] In some embodiments, the disease is associated with decreased expression of a functional version of a mitochondrial protein compared to unaffected controls.
[0068] In some embodiments, the disease is associated with decreased stability of a functional version of a mitochondrial protein compared to unaffected controls.
[0069] In some embodiments, the disease is associated with increased ubiquitination and degradation of mitochondrial proteins compared to unaffected controls.
[0070] In some embodiments, the disease is a genetic disease.
[0071] In some embodiments, the disease is CHD2 encephalopathy, CDKL5 deficiency disorder, SETD5 syndrome, CAMTA1 syndrome, early infantile epileptic encephalopathy type 2, childhood-onset epileptic encephalopathy, 1p36 deletion syndrome, Rett syndrome, Kabuki syndrome 1, mental retardation autosomal dominant 23, Mowat-Wilson syndrome, cerebellar ataxia, Fragile X syndrome, retinitis pigmentosa 13, Smith-Maginis syndrome, Rubinstein-Taybi syndrome, neurofibromatosis (e.g., type 1), Wiedemann-Steiner syndrome, Schifflim-Hitz-Weiss syndrome, Sotos syndrome, MED13L syndrome, SMC1A syndrome, Nicolaides-Baraitser syndrome, ARID1B-related disorder, White-Sutton syndrome, KAT6B disorder, Shea-Gibbs syndrome, Menke-Henecum syndrome 2, IQSEC2-related disorder, TCF20-related disorder, Bainbridge-Lopers syndrome, and KATA6 syndrome.
[0072] In some embodiments, the disease is a haploinsufficiency disease. In some embodiments, the haploinsufficiency disease is selected from the group consisting of early infantile epileptic encephalopathy type 2, childhood-onset epileptic encephalopathy, 1p36 deletion syndrome, Rett syndrome, mental retardation autosomal dominant 23, Mowat-Wilson syndrome, cerebellar ataxia, Smith-Maginis syndrome, or neurofibromatosis (e.g., type 1).
[0073] In some embodiments, the fusion protein is administered at a therapeutically effective dose. In some embodiments, the fusion protein is administered systemically or locally. In some embodiments, the fusion protein is administered intravenously, subcutaneously, or intramuscularly. [Brief explanation of the drawings]
[0074] [Figure 1]Figures 1A-1D provide schematic diagrams of exemplary fusion proteins described herein. Figure 1A is a schematic diagram of an engineered deubiquitinase comprising, at its N'- to C'-terminus, a VHH that specifically binds a nuclear target protein and a catalytic domain of a deubiquitinase. In this specific embodiment, the C-terminus of the VHH is directly linked to the N-terminus of the catalytic domain of the deubiquitinase. Figure 1B is a schematic diagram of an engineered deubiquitinase comprising, at its N'- to C'-terminus, a catalytic domain of a deubiquitinase that specifically binds a nuclear target protein and a VHH that specifically binds a nuclear target protein. In this specific embodiment, the C-terminus of the catalytic domain of the deubiquitinase is directly linked to the N-terminus of the VHH. Figure 1C is a schematic diagram of an engineered deubiquitinase comprising, at its N'- to C'-terminus, a VHH that specifically binds a nuclear target protein and a catalytic domain of a deubiquitinase. In this specific embodiment, the C-terminus of the VHH is indirectly connected to the N-terminus of the catalytic domain of a deubiquitinase via a peptide linker. Figure ID is a schematic diagram of an engineered deubiquitinase comprising a catalytic domain of a deubiquitinase that specifically binds to a nuclear target protein from its N' to C' terminus and a VHH that specifically binds to a nuclear target protein. In this specific embodiment, the C-terminus of the catalytic domain of the deubiquitinase is indirectly connected to the N-terminus of the VHH via a peptide linker. [Figure 2] FIG. 1 is a schematic diagram of the assay utilized in Example 3 to screen the effect of targeted deubiquitination of different nuclear proteins on target protein expression. [Figure 3] FIG. 1 is a bar graph showing the fold change in expression of SNRPG protein compared to the control (deubiquitinase without nanobody targeting the alpha-tag). [Figure 4] FIG. 1 is a bar graph showing the fold change in LSM2 protein expression compared to the control (deubiquitinase without nanobody targeting the alpha-tag). [Figure 5]1 is a bar graph showing the fold change in NUPR2 protein expression compared to the control (deubiquitinase without nanobody targeting the alpha-tag). DETAILED DESCRIPTION OF THE INVENTION
[0075] 5. Detailed Description 5.1 Overview Ubiquitination is a process in which ubiquitin ligases mediate the addition of ubiquitin, a 76-amino acid regulatory protein, to substrate proteins. Ubiquitination typically begins with the attachment of a single ubiquitin molecule to a lysine amino acid residue on the substrate protein. (Mevissen T. et al. Mechanisms of Deubiquitinase Specificity and Regulation Annual Review of Biochemistry 86:1, 159-192 (2017), the entire contents of which are incorporated herein by reference.) These monoubiquitination events are abundant and serve a variety of functions. Ubiquitin itself contains seven lysine residues, all of which can be ubiquitinated, resulting in polyubiquitinated proteins. Komander, D. et al. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 10, 550-563 (2009), the entire contents of which are incorporated herein by reference. Mono- and polyubiquitination can have multiple effects on substrate proteins, including marking the substrate protein for degradation via the proteasome, changing the cellular location of the protein, changing the activity of the protein, and / or promoting or preventing normal protein interactions. See, for example, Hershko A. et al. The ubiquitin system. Annu Rev Biochem. 67:425-79 (1998); Nandi D, et al. The ubiquitin-proteasome system. J Biosci. Mar;31(1):137-55 (2006), the entire contents of each of which are incorporated herein by reference. The effects of ubiquitination can be reversed or prevented by removing the ubiquitin protein from the substrate protein. The removal of ubiquitin from substrate proteins is mediated by deubiquitinase (DUB) proteins.
[0076] Many genetic disorders are associated with or caused by a decrease in the expression level or stability of functional nuclear proteins. For example, haploinsufficiency genetic disorders are caused by the presence of a single copy of a wild-type allele heterozygously combined with a loss-of-function variant allele, resulting in an insufficient level of expressed functional protein to produce a typical phenotype. See, for example, Johnson, A. et al., Causes and effects of haploinsufficiency. Biol Rev, 94: 1774-1785 (2019), the entire contents of which are incorporated herein by reference. Haploinsufficiency can result from de novo or inherited loss-of-function mutations in the variant allele, resulting in little or no functional protein production. Other genetic disorders result from the ubiquitination and subsequent degradation of the variant but functional protein, resulting in a decrease in functional protein expression.
[0077] The present disclosure provides, inter alia, novel fusion proteins comprising a catalytic domain of a deubiquitinase (or a functional fragment thereof) and a targeting moiety, such as a VHH, that specifically binds to a target nuclear protein. In some embodiments, a decrease in the expression of a functional version of the target nuclear protein or a decrease in the stability of a functional version of the target nuclear protein is associated with a disease phenotype. As such, the fusion proteins described herein are particularly useful for treating genetic diseases characterized by a decrease in the expression level of a functional target nuclear protein or the stability of the target nuclear protein. Upon expression of the fusion protein by a host cell, the catalytic domain of the deubiquitinase is specifically targeted to and deubiquitinates the target nuclear protein, resulting in an increase in the expression of the target nuclear protein to a level sufficient, for example, to alleviate a disease phenotype.
[0078] 5.2 Definition The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described.
[0079] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to which this disclosure pertains.For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary of Biochemistry and Molecular Biology, Revised, 2000, Oxford University Press provide those skilled in the art with a general dictionary of many of the terms used in this disclosure.
[0080] It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the claimed subject matter. In this application, the use of the singular includes the plural unless specifically stated otherwise.
[0081] It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Furthermore, the use of the term "including" as well as other forms such as "include," "includes," and "included" is not limiting.
[0082] Whenever an embodiment is described herein using the word "comprising," it is understood that other similar embodiments described by "consisting of" and / or "consisting essentially of" are also provided.
[0083] The term "and / or" as used herein should be interpreted as a specific disclosure of two specific features or components, each with or without the other. Thus, when used in phrases such as "A and / or B" herein, the term "and / or" is intended to include "A and B," "A or B," "A" (single), and "B" (single). Similarly, when used in phrases such as "A, B, and / or C," the term "and / or" is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (single); B (single); and C (single).
[0084] Units, prefixes, and symbols are denoted in the format adopted by the International System of Units (SI). Numerical ranges are inclusive of the numbers defining the range. The headings provided herein are not intended to limit the various aspects of the disclosure, which can be had by reference to the specification in its entirety. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.
[0085] As described herein, any concentration range, percentage range, ratio range, or integer range should be understood to include any integer value within the stated range, and fractions thereof, where appropriate (such as integer tenths and hundredths), unless otherwise indicated.
[0086] The terms "about" or "essentially consisting of" refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which depends in part on how the value or composition is measured or determined, i.e., the limitations of the measurement system. For example, "about" or "essentially consisting of" can mean within one or more standard deviations, as practiced in the art. Alternatively, "about" or "essentially consisting of" can mean a range of up to 20%. Furthermore, particularly with respect to biological systems or processes, these terms can mean up to an order of magnitude difference from the value or up to five times the value. When specific values or compositions are provided in the applications and claims, unless otherwise stated, the meaning of "about" or "essentially consisting of" should be assumed to be within an acceptable error range for that particular value or composition.
[0087] As used herein, the term "catalytic domain" with respect to a deubiquitinating enzyme refers to the amino acid sequence of the deubiquitinating enzyme, or a variant thereof, that is capable of mediating deubiquitination of a target protein. The catalytic domain may comprise the naturally occurring amino acid sequence of the deubiquitinating enzyme, or it may comprise a variant amino acid sequence of the naturally occurring deubiquitinating enzyme. The catalytic domain may comprise the minimal amino acid sequence of the deubiquitinating enzyme to mediate deubiquitination of a target protein. The catalytic domain may comprise a larger than minimal amino acid sequence of the deubiquitinating enzyme to mediate deubiquitination of a target protein.
[0088] The terms "polynucleotide" and "nucleic acid sequence" are used interchangeably herein and refer to a polymer of DNA or RNA. Polynucleotide sequences can be single- or double-stranded; contain natural, non-natural, or modified nucleotides; and contain natural, non-natural, or modified internucleotide linkages, such as phosphoramidate or phosphorothioate linkages instead of the phosphodiesters found between nucleotides in unmodified polynucleotide sequences. Polynucleotide sequences include, but are not limited to, all polynucleotide sequences obtained by any means available in the art, including, but not limited to, recombinant means, such as cloning polynucleotide sequences from recombinant libraries or cell genomes, using conventional cloning techniques and polymerase chain reaction, etc., as well as by synthetic means.
[0089] The terms "amino acid sequence" and "polypeptide" are used interchangeably herein to refer to a polymer of amino acids joined by one or more peptide bonds.
[0090] The term "functional variant" as used herein with respect to a protein or polypeptide refers to a protein that contains at least one amino acid modification (e.g., substitution, deletion, addition) compared to the amino acid sequence of a reference protein that retains at least one particular function. In some embodiments, the reference protein is a wild-type protein. For example, a functional variant of an IL-2 protein can refer to an IL-2 protein that contains an amino acid substitution compared to the wild-type IL-2 protein that retains the ability to bind to the intermediate-affinity IL-2 receptor but eliminates the protein's ability to bind to the high-affinity IL-2 receptor. Not all functions of the reference wild-type protein need be retained by a functional variant of a protein. In some cases, one or more functions are selectively reduced or eliminated.
[0091] The term "functional fragment" as used herein in relation to a protein or polypeptide refers to a fragment of a reference protein that retains at least one specific function. For example, a functional fragment of an anti-HER2 antibody may refer to a fragment of an anti-HER2 antibody that retains the ability to specifically bind to HER2 antigen. Not all functions of the reference protein need to be retained by a functional fragment of a protein. In some cases, one or more functions are selectively reduced or eliminated.
[0092] As used herein, the term "modified" with respect to a polynucleotide sequence refers to a polynucleotide sequence that contains at least one substitution, alteration, inversion, addition, or deletion of a nucleotide compared to a reference polynucleotide sequence. A modification can include a non-naturally occurring nucleotide. As used herein, the term "modified" with respect to an amino acid sequence refers to an amino acid sequence that contains at least one substitution, alteration, inversion, addition, or deletion of an amino acid residue compared to a reference amino acid sequence. A modification can include the inclusion of a non-naturally occurring amino acid residue.
[0093] As used herein, the term "derived" with respect to an amino acid sequence refers to an amino acid sequence that has at least 80% sequence identity with a reference naturally occurring amino acid sequence. For example, a catalytic domain derived from a naturally occurring deubiquitinase means that the catalytic domain has an amino acid sequence that has at least 80% sequence identity with the sequence of the deubiquitinase catalytic domain from which it is derived. The term "derived" as used herein does not refer to any particular process or method for obtaining the amino acid sequence. For example, the amino acid sequence may be chemically synthesized or recombinantly synthesized.
[0094] The term "fusion protein" and grammatical equivalents, as used herein, refer to a protein comprising an amino acid sequence derived from at least two separate proteins. The amino acid sequences of the at least two separate proteins may be directly connected via a peptide bond; or may be operably connected via an amino acid linker. Thus, the term fusion protein encompasses embodiments in which, for example, the amino acid sequence of protein A is directly connected to the amino acid sequence of protein B via a peptide bond (protein A-protein B), as well as embodiments in which, for example, the amino acid sequence of protein A is operably connected to the amino acid sequence of protein B via an amino acid linker (protein A-linker-protein B).
[0095] The term "fused" and its grammatical equivalents, as used herein, refers to the operative connection of an amino acid sequence derived from one protein to an amino acid sequence derived from a different protein. The term fused encompasses both the direct connection of two amino acid sequences via a peptide bond and the indirect connection via an amino acid linker.
[0096] An "isolated antibody" refers to an antibody that is substantially free of other antibodies with different antigenic specificities (e.g., an isolated antibody that specifically binds to HER2 is substantially free of antibodies that specifically bind to antigens other than HER2). However, an isolated antibody that specifically binds to HER2 may cross-react with other antigens, such as HER2 molecules from different species. Moreover, an isolated antibody may be substantially free of other cellular material and / or chemicals. In comparison, an "isolated" nucleic acid refers to a substance whose nucleic acid composition is significantly different, i.e., has a chemical identity, properties, and utility distinct from those of nucleic acids found in nature. For example, unlike native DNA, isolated DNA is an independent piece of native DNA and is not an integral part of the larger structural complex, chromosome, in which it is found in nature. Furthermore, unlike native DNA, isolated DNA can be used as a PCR primer or hybridization probe to measure gene expression and detect biomarker genes or mutations to, among other things, diagnose disease or predict the effectiveness of therapeutic drugs. The isolated nucleic acid may also be purified using standard techniques well known in the art so that it is substantially free of other cellular components or other contaminants, such as other cellular nucleic acids or proteins.
[0097] As used herein, the term "antibody" or "antibodies" is used in the broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments (i.e., antigen-binding fragments as defined herein), so long as they exhibit the desired antigen-binding activity. Thus, the term antibody includes, for example, full-length antibodies, antigen-binding fragments of full-length antibodies, molecules comprising antibody CDRs, VH regions, and / or VL regions; and antibody-like scaffolds (e.g., fibronectin). Examples of antibodies include monoclonal antibodies, recombinantly produced antibodies, monospecific antibodies, multispecific antibodies (including bispecific antibodies), human antibodies, humanized antibodies, chimeric antibodies, immunoglobulins, synthetic antibodies, tetrameric antibodies comprising two heavy chain and two light chain molecules, antibody light chain monomers, antibody heavy chain monomers, antibody light chain dimers, antibody heavy chain dimers, antibody light chain-antibody heavy chain pairs, intrabodies, heteroconjugate antibodies, antibody-drug conjugates, single domain antibodies (e.g., VHH, (VHH)2), monovalent antibodies, single chain antibodies, single chain Fvs (scFv; (scFv)2), camelized antibodies, affybodies, Fab fragments (e.g., Fab, single chain Fab (scFab), F(ab')2 fragments, disulfide-linked Fvs (sdFv), anti-idiotypic (anti-Id) antibodies (e.g., anti-anti-Id antibodies, Antibodies include, but are not limited to, antibodies, diabodies, tribodies, and antibody-like scaffolds (e.g., fibronectin), Fc fusions (e.g., Fab-Fc, scFv-Fc, VHH-Fc, (scFv)2-Fc, (VHH)2-Fc, and antigen-binding fragments of any of the above, as well as conjugates or fusion proteins comprising any of the above. In certain embodiments, antibodies described herein refer to polyclonal antibody populations. In certain embodiments, antibodies described herein refer to monoclonal antibody populations. Antibodies may be of any type (e.g., IgG, IgE, IgM, IgD, IgA, or IgY), any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2), or any subclass (e.g., IgG 2a or IgG2b ) immunoglobulin (Ig) molecules. In certain embodiments, the antibodies described herein are IgG antibodies, or classes (e.g., human IgG1 or IgG4) or subclasses thereof. In specific embodiments, the antibodies are humanized monoclonal antibodies. In another specific embodiment, the antibodies are human monoclonal antibodies.
[0098] The term "full-length antibody," as used herein, refers to an antibody having a structure substantially similar to that of a native antibody, comprising two heavy chains and two light chains interconnected by disulfide bonds. In some embodiments, the two heavy chains comprise substantially identical amino acid sequences; the two light chains comprise substantially identical amino acid sequences. Antibody chains can be substantially identical, but not completely identical, if they differ due to post-translational modifications such as C-terminal truncation of lysine residues, alternative glycosylation patterns, etc.
[0099] The terms "antigen-binding fragment" and "antigen-binding domain" are used interchangeably herein and refer to one or more polypeptides other than a full-length antibody, which polypeptide is capable of specifically binding to an antigen and includes a portion of a full-length antibody (e.g., VH, VL). Exemplary antigen-binding fragments include, but are not limited to, single-domain antibodies (e.g., VHH, (VHH)2), single-chain antibodies, single-chain Fvs (scFv; (scFv)2), camelized antibodies, affibodies, Fab fragments (e.g., Fab, single-chain Fab (scFab), F(ab')2 fragments, and disulfide-linked Fvs (sdFv). An antigen-binding domain may be part of a larger protein, such as a full-length antibody.
[0100] The term "(scFv)2" as used herein refers to an antibody comprising a first and a second scFv operably connected (e.g., via a linker). The first and second scFvs can specifically bind to the same or different antigens. In some embodiments, the first and second scFvs are operably connected by an amino acid via an amino acid linker.
[0101] The term "(VHH)2" as used herein refers to an antibody comprising a first and a second VHH that are operably connected (e.g., via a linker). The first and second VHHs can specifically bind to the same or different antigens. In some embodiments, the first and second VHHs are operably connected by an amino acid via an amino acid linker.
[0102] The term "Fab-Fc," as used herein, refers to an antibody comprising a Fab operably linked to an Fc domain or a subunit of an Fc domain. The full-length antibodies described herein comprise two Fabs, one Fab operably linked to one Fc domain and the other Fab operably linked to a second Fc domain.
[0103] The term "scFv-Fc," as used herein, refers to an antibody comprising an scFv operably linked to an Fc domain or a subunit of an Fc domain.
[0104] The term "VHH-Fc", as used herein, refers to an antibody comprising a VHH operably linked to an Fc domain or a subunit of an Fc domain.
[0105] The term "(scFv)2-Fc," as used herein, refers to an (scFv)2 operably linked to an Fc domain or a subunit of an Fc domain.
[0106] The term "(VHH)2-Fc," as used herein, refers to a (VHH)2 operably linked to an Fc domain or a subunit of an Fc domain.
[0107] "Antibody-like scaffolds" are known in the art; for example, fibronectin and designed ankyrin repeat proteins (DARPins) have been used as scaffolds to replace antigen-binding domains. See, for example, Gebauer and Skerra, Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13:245-255 (2009) and Stumpp et al., Darpins: A new generation of protein therapeutics. Drug Discovery Today 13:695-701 (2008). Exemplary antibody-like scaffold proteins include, but are not limited to, lipocalins (Anticalins), Protein A-derived molecules such as the Z domain (Affibody), A domain (Avimer / Maxibody) of Protein A, serum transferrin (trans-body); designed ankyrin repeat proteins (DARPins), VNAR fragments, fibronectin (AdNectin), C-type lectin domains (tetranectins); the variable domain of the novel antigen receptor beta-lactamase (VNAR fragment), human gamma-crystallin or ubiquitin (Affilin molecules); Kunitz-type domains of human protease inhibitors, microbodies such as proteins from the knottin family, peptide aptamers and fibronectin (Adnectin).
[0108] As used herein, the term "CDR" or "complementarity-determining region" refers to the discontinuous antigen-binding sites found within the variable regions of both heavy and light chain polypeptides. These particular regions are described by Kabat et al., J. Biol. Chem. 252, 6609-6616 (1977) and Kabat et al., Sequences of proteins of immunological interest. (1991), all of which are incorporated herein by reference in their entireties. Unless otherwise specified, the term "CDR" refers to a CDR as defined by Kabat et al., J. Biol. Chem. 252, 6609-6616 (1977) and Kabat et al., Sequences of proteins of immunological interest. (1991).
[0109] As used herein, the term "framework (FR) amino acid residues" refers to amino acids in the framework region of an antibody variable region. The term "framework region" or "FR region" as used herein includes amino acid residues that are part of the variable region but are not part of the CDRs (e.g., using the Kabat definition of CDRs).
[0110] As used herein, the term "heavy chain," when used in reference to an antibody, can refer to any of the distinct types, e.g., alpha (α), delta (δ), epsilon (ε), gamma (γ), and mu (μ), which include the subclasses of IgG, e.g., IgG1, IgG2, IgG3, and IgG4, based on the amino acid sequence of the constant domain, and give rise to antibodies of the IgA, IgD, IgE, IgG, and IgM classes, respectively.
[0111] As used herein, the term "light chain," when used in reference to an antibody, can refer to any distinct type, e.g., kappa (κ) or lambda (λ), based on the amino acid sequence of the constant domain. Light chain amino acid sequences are well known in the art. In a specific embodiment, the light chain is a human light chain.
[0112] As used herein, the term "variable region" refers to a portion of an antibody, generally a portion of either the light or heavy chain, typically the amino-terminal approximately 110-120 amino acids or 110-125 amino acids in the mature heavy chain and approximately 90-115 amino acids in the mature light chain, which differ extensively in sequence among antibodies and are used to determine the binding and specificity of a particular antibody for its particular antigen. Sequence variability is concentrated in regions called complementarity-determining regions (CDRs), whereas the more highly conserved regions in the variable domain are called framework regions (FRs). While not wishing to be bound by a particular mechanism or theory, the CDRs of the light and heavy chains are primarily responsible for the interaction and specificity of the antibody with its antigen. In certain embodiments, the variable region is a human variable region. In certain embodiments, the variable region comprises rodent or murine CDRs and human framework regions (FRs). In certain embodiments, the variable region is a primate (e.g., non-human primate) variable region. In certain embodiments, the variable region comprises rodent or murine CDRs and primate (e.g., non-human primate) framework regions (FR).
[0113] The terms "VL" and "VL domain" are used interchangeably to refer to the light chain variable region of an antibody.
[0114] The terms "VH" and "VH domain" are used interchangeably to refer to the heavy chain variable region of an antibody.
[0115] As used herein, the terms "constant region" and "constant domain" are interchangeable and are common in the art. The constant region is the carboxyl-terminal portion of an antibody portion, e.g., the light chain and / or heavy chain, that is not directly involved in binding the antibody to an antigen but can exhibit various effector functions, such as interaction with Fc receptors (e.g., Fc gamma receptors). The constant region of an immunoglobulin (Ig) molecule generally has a more conserved amino acid sequence than the immunoglobulin (Ig) variable domain.
[0116] The term "Fc region," as used herein, refers to the C-terminal region of an immunoglobulin (Ig) heavy chain comprising, from N- to C-terminus, at least a CH2 domain operably connected to a CH3 domain. In some embodiments, the Fc region comprises an immunoglobulin (Ig) hinge region operably connected to the N-terminus of the CH2 domain. Examples of proteins with engineered Fc regions can be found in Saunders 2019 (KO Saunders, "Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life," 2019, Frontiers in Immunology, Vol. 10, Art. 1296, pp. 1-20, incorporated herein by reference).
[0117] As used herein, the term "EU numbering system" refers to the EU numbering convention for antibody constant regions as described in Edelman, GM et al., Proc. Natl. Acad. USA, 63, 78-85 (1969) and Kabat et al., Sequences of Proteins of Immunological Interest, US Dept. Health and Human Services, 5th edition, 1991, each of which is incorporated herein by reference in its entirety.
[0118] As used herein, the term "Kabat numbering system" refers to the Kabat numbering convention for antibody variable regions. See, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, US Dept. Health and Human Services, 5th edition, 1991. Unless otherwise noted, the numbering of antibody variable regions is indicated by the Kabat numbering system.
[0119] As used herein, the term "specifically binds to" refers to a molecule that binds to an antigen (e.g., an epitope or immune complex), and such binding is understood by those of skill in the art. For example, a molecule that specifically binds to an antigen may generally bind with lower affinity to other peptides or polypeptides, as determined, for example, by immunoassay, BIAcore®, KinExA 3000 instrument (Sapidyne Instruments, Boise, ID), or other assays known in the art. In specific embodiments, molecules that specifically bind to an antigen have a K that is lower than the K that these molecules have when nonspecifically binding to another antigen. A K at least 2 logs (e.g., a factor of 10), 2.5 logs, 3 logs, 4 logs, or more A The antibody binds to an antigen at a specific region. Those skilled in the art will recognize that the antibody described herein may specifically bind to more than one antigen (e.g., via different regions of the antibody molecule). The term "specifically binds" includes molecules that cross-react with the same antigen of different species. For example, an antigen-binding domain that specifically binds to human CD20 may cross-react with CD20 of another species (e.g., cynomolgus monkey, or mouse) and still be considered herein to specifically bind to human CD20.
[0120] "Affinity" refers to the total strength of non-covalent interactions between a single binding site of a molecule (e.g., a receptor) and its binding partner (e.g., a ligand). Unless otherwise indicated, "binding affinity" as used herein refers to the intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antigen-binding moiety and an antigen, or a receptor and its ligand). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD), which is the ratio of the dissociation rate constant to the association rate constant (koff and kon, respectively). Thus, equivalent affinities can involve different rate constants as long as the ratio of the rate constants remains the same. Affinity can be measured by established methods known in the art, including those described herein. A particular method for measuring affinity is surface plasmon resonance (SPR).
[0121] Determining "percent identity" between two sequences (e.g., amino acid sequences or nucleic acid sequences) can be accomplished using a mathematical algorithm. Identity measures the percent of identical matches between the smaller of two or more sequences, with gap alignment (if any) addressed by a particular mathematical model or computer program (i.e., "algorithm"). A specific, non-limiting example of a mathematical algorithm utilized for comparing two sequences is the algorithm of Karlin S & Altschul SF (1990) PNAS 87: 2264-2268, modified as in Karlin S & Altschul SF (1993) PNAS 90: 5873-5877, each of which is incorporated herein by reference in its entirety. Such an algorithm is incorporated into the BLASTN, BLASTP, and BLASTX programs of Altschul SF et al., (1990) J Mol Biol 215: 403, which are incorporated herein by reference in their entirety. BLAST nucleotide searches can be performed using the NBLAST nucleotide program parameters, for example, score=100, word length=12, to obtain nucleotide sequences homologous to the nucleic acid molecules described herein. BLAST protein searches can be performed using the BLASTP program parameters, for example, with default settings, to obtain amino acid sequences homologous to the protein molecules described herein. Gapped BLAST can be used to obtain gapped alignments for comparison purposes, as described in Altschul SF et al., (1997) Nuc Acids Res 25: 3389-3402, the entire contents of which are incorporated herein by reference. Alternatively, PSI BLAST can be used to perform an iterated search that detects distant relationships between molecules (ibid.).When utilizing BLAST, Gapped BLAST, and PSI Blast programs, the default parameters of the respective programs (e.g., BLASTP and BLASTN) can be used (see, for example, the National Center for Biotechnology Information (NCBI) World Wide Web at ncbi.nlm.nih.gov). Another specific, non-limiting example of a mathematical algorithm utilized for comparing sequences is the algorithm of Myers and Miller, 1988, CABIOS 4:11-17, which is incorporated herein by reference in its entirety. Such an algorithm is incorporated into the ALIGN program (version 2.0), which is part of the GCG sequence alignment software package. When utilizing the ALIGN program to compare amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, typically, only exact matches are counted. As mentioned above, identity percentage is based on the amino acid match between the smaller of the two proteins.Therefore, for example, using NCBI Basic Local Alignment Tool-BLASTP program with default settings (search parameters: word size 3, expectation value 0.05, hit list 100, gap cost 11,1; matrix BLOSUM62, filter string: F; genetic code: 1; window size: 40; threshold: 11; composition-based statistics: 2; Karlin-Altschul statistics: lambda: 0.31293; 0.267; K: 0.132922; 0.041; H: 0.401809; 0.14; and relative statistics: effective search space: 288906), the identity percentage between SEQ ID NO: 80 and SEQ ID NO: 423 is 100% identity.
[0122] As used herein, the term "operably linked" refers to the association of polynucleotide or amino acid sequence elements in a functional relationship. For example, a polynucleotide sequence is operably connected when it is placed into a functional relationship with another polynucleotide sequence. In some embodiments, a transcriptional regulatory polynucleotide sequence, such as a promoter, enhancer, or other expression control element, is operably linked to a protein-encoding polynucleotide sequence if it affects the transcription of the protein-encoding polynucleotide sequence.
[0123] The terms "subject" and "patient" are used interchangeably herein and include any human or non-human animal. The term "non-human animal" includes, but is not limited to, vertebrates such as non-human primates, sheep, dogs, and rodents such as mice, rats, and guinea pigs. In some embodiments, the subject is a human.
[0124] As used herein, the term "administering" refers to the physical introduction of a therapeutic agent (or a precursor of a therapeutic agent that is metabolized or transformed in the subject's body to produce a therapeutic agent in vivo) into a subject using any of a variety of methods and delivery systems known to those of skill in the art. Exemplary routes include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal, or other parenteral routes of administration, for example, by injection or infusion. The term "parenteral administration," as used herein, refers to modes of administration other than enteral and topical administration, usually by injection, and includes, but is not limited to, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion, as well as in vivo electroporation. Therapeutic agents may be administered via non-parenteral routes or orally. Other non-parenteral routes include topical, epidermal, or mucosal routes of administration, e.g., intranasal, vaginal, rectal, sublingual, or topical. Administration can also be, for example, single, multiple, and / or over one or more extended periods.
[0125] A "therapeutically effective amount" or "therapeutically effective dose" of a drug or therapeutic agent is any amount of drug that, when used alone or in combination with another therapeutic agent, protects a subject from onset of disease or promotes regression of the disease, as evidenced by a reduction in the severity of disease symptoms, an increase in the frequency and duration of disease-free symptom intervals, or prevention of functional impairment or disability due to the affliction of the disease. The ability of a therapeutic agent to promote regression of the disease can be evaluated using a variety of methods known to those of skill in the art, for example, by assaying the activity of the agent in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or in in vitro assays.
[0126] The terms "disease," "disorder," and "syndrome" are used interchangeably herein.
[0127] As used herein, the terms "treat," "treating," "treatment," and the like refer to alleviating or ameliorating a disease and / or its associated symptoms, or achieving a desired pharmacological and / or physiological effect. It is recognized that treating a disease does not require, but does not preclude, the complete disappearance of the disease or its associated symptoms. In some embodiments, the effect is therapeutic, i.e., the effect partially or completely reduces, reduces, counteracts, alleviates, relieves, reduces the intensity of, or cures the disease and / or adverse symptoms that may result from the disease, but is not limited to this. In some embodiments, the effect is prophylactic, i.e., the effect prevents or prevents the occurrence or recurrence of the disease. To this end, the methods disclosed herein comprise administering a therapeutically effective amount of a composition described herein.
[0128] 5.3 Fusion proteins In certain aspects, provided herein are fusion proteins comprising an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof; and a targeting domain comprising a moiety that specifically binds to a target cytosolic protein.
[0129] 5.3.1 Effector domain In some embodiments, the effector domain comprises a catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof. In some embodiments, the deubiquitinase is human. In some embodiments, the catalytic domain is derived from a naturally occurring deubiquitinase (e.g., a naturally occurring human deubiquitinase).
[0130] In some embodiments, the amino acid sequence of the effector domain comprises the amino acid sequence of a full-length deubiquitinase, hi some embodiments, the amino acid sequence of the effector domain comprises the amino acid sequence of a catalytic domain of a deubiquitinase and additional amino acid sequences at the N-terminus, C-terminus, or N-terminus and C-terminus of the catalytic domain.
[0131] In some embodiments, the catalytic domain comprises the native amino acid sequence of a deubiquitinase. In some embodiments, the catalytic domain comprises a variant of a native deubiquitinase. In some embodiments, the amino acid sequence of the catalytic domain of the fusion protein is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of a native deubiquitinase. In some embodiments, the amino acid sequence of the catalytic domain of the fusion protein comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 amino acid modifications compared to the amino acid sequence of the catalytic domain of a native deubiquitinase.
[0132] In some embodiments, the catalytic domain comprises the minimal amino acid sequence of a naturally occurring deubiquitinase sufficient to mediate deubiquitination of a target protein, hi some embodiments, the catalytic domain comprises a larger than minimal amino acid sequence of a naturally occurring deubiquitinase sufficient to mediate deubiquitination of a target protein.
[0133] In some embodiments, the deubiquitinating enzyme is a cysteine protease or a metalloprotease. In some embodiments, the deubiquitinating enzyme is a cysteine protease. In some embodiments, the deubiquitinating enzyme is a metalloprotease. In some embodiments, the deubiquitinating enzyme is a ubiquitin-specific protease (USP), a ubiquitin C-terminal hydrolase (UCH), a Machado-Josephine domain protease (MJD), an ovarian tumor protease (OTU), a MINDY protease, or a ZUFSP protease.
[0134] Exemplary deubiquitinating enzymes include USP1, USP2, USP3, USP4, USP5, USP6, USP7, USP8, USP9X, USP9Y, USP10, USP11, USP12, USP13, USP14, USP15, USP16, USP17, USP17L2, USP17L3, USP17L4, USP17L5, USP17L7, USP17L8, USP18, USP19, USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, USP46, USP47, USP48, USP49, USP50, USP51, USP52, USP53, USP54, USP55, USP56, USP57, USP58, USP59, USP60, USP61, USP62, USP63, USP64, USP65, USP66, USP67, USP68, USP69, USP70, USP71, USP72, USP73, USP74, USP75, USP76, USP77, USP78, USP79, USP80, USP81, USP82, USP83, USP84, USP85, USP86, USP87, USP88, USP89, USP90, USP91, USP92, Exemplary deubiquitinases for use in the present disclosure include, but are not limited to, SP27X, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, USP46, BAP1, UCHL1, UCHL3, UCHL5, ATXN3, ATXN3L, OTUB1, OTUB2, MINDY1, MINDY2, MINDY3, MINDY4, and ZUP1. Exemplary deubiquitinases for use in the present disclosure are also disclosed in Komander, D. et al. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 10, 550-563 (2009), the entire contents of which are incorporated herein by reference.
[0135] In some embodiments, the deubiquitinating enzyme is USP1, USP2, USP3, USP4, USP5, USP6, USP7, USP8, USP9X, USP9Y, USP10, USP11, USP12, USP13, USP14, USP15, USP16, USP17, USP17L2, USP17L3, USP17L4, USP17L5, USP17L7, USP17L8, USP18, USP19, USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP39L10, USP39L11, USP39L12, USP39L13, USP39L14, USP39L15, USP39L16, USP39L17, USP39L18, USP39L19, USP39L19, USP39L20, USP39L21, USP39L22, USP39L23, USP39L24, USP39L25, USP39L30, USP39L41, USP39L52, USP39L6, USP39L73, USP39L84, USP39L95, USP39L10, USP39L11, USP39L12, USP39L13, USP39L14, USP39L15, USP39L16, USP39L17, USP39L18, USP 9, USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27X, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, USP43, USP44, USP45, and USP46.
[0136] In some embodiments, the deubiquitinase is BAP1, UCHL1, UCHL3, or UCHL5. In some embodiments, the deubiquitinase is ATXN3 or ATXN3L. In some embodiments, the deubiquitinase is OTUB1 or OTUB2. In some embodiments, the deubiquitinase is MINDY1, MINDY2, MINDY3, or MINDY4. In some embodiments, the deubiquitinase is ZUP1. In some embodiments, the deubiquitinase is Jab1 / Mov34 / Mpr1 Pad1 N-terminal+(MPN+) (JAMM) domain protease.
[0137] In some embodiments, the deubiquitinase is a deubiquitinase listed in Table 1. In some embodiments, the amino acid sequence of the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of a deubiquitinase in Table 1. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the catalytic domain of a deubiquitinase in Table 1. In some embodiments, the effector domain comprises a functional fragment of a deubiquitinase in Table 1. In some embodiments, the effector domain of a deubiquitinase comprises a functional variant of a deubiquitinase in Table 1. In some embodiments, the catalytic domain comprises a functional fragment of the catalytic domain of a deubiquitinase in Table 1. In some embodiments, the catalytic domain comprises a functional variant of the catalytic domain of a deubiquitinase in Table 1.
[0138] In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 1-112. In some embodiments, the deubiquitinase consists of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 1-112.
[0139] In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:2. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 3. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 4. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 5. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 6. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:7.In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 8. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:9. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 10. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 11. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 12. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 13. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:14.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 15. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 16. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 17. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 18. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 19. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:20. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:21.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 22. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 23. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 24. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 25. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 26. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 27. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:28.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 29. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 30. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 31. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 32. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 33. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 34. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:35.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 36. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 37. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:38. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 39. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 40. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 41. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 42. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 43. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 44. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:45.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 46. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 47. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 48. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 49. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 50. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 51. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:52.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 53. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 54. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 55. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 56. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 57. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 58. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:59.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 60. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 61. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 62. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 63. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 64. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 65. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:66.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 67. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 68. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 69. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 70. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 71. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 72. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:73.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 74. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 75. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 76. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 77. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 78. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 79. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 80. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:81. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:82.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 83. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 84. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 85. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:86. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 87. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:88. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:89.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 90. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:91. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 92. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:93. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 94. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:95. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:96.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 97. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:98. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 99. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 100. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 101. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 102. In some embodiments, the deubiquitinase comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:103.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 104. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 105. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 106. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 107. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 108. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 109. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:110.In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 111. In some embodiments, the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 112.
[0140] In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of any one of SEQ ID NOs: 1-112. In some embodiments, the amino acid sequence of the effector domain consists of an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of any one of SEQ ID NOs: 1-112.
[0141] In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 1. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:2. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 3. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 4. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 5. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 6.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 7. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:8. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 9. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 10. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 11. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 12.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 13. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 14. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 15. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 16. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 17. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 18.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 19. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:20. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 21. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 22. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 23. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 24.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 25. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 26. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 27. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 28. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 29. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 30.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 31. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 32. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 33. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 34. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 35. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 36. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 37. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 38.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 39. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 40. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 41. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 42. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 43. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 44.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 45. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 46. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 47. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 48. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 49. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:50.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 51. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 52. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 53. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 54. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 55. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 56.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 57. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 58. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 59. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 60. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 61. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 62.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 63. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 64. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 65. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 66. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 67. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 68. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 69. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 70.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 71. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 72. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 73. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 74. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 75. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 76.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 77. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 78. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 79. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:80. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 81. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 82.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 83. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 84. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 85. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 86. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 87. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:88.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 89. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:90. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 91. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 92. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 93. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:94.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 95. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 96. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 97. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO:98. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 99. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 100. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 101. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 102.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 103. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 104. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 105. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 106. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 107. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 108.In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 109. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 110. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 111. In some embodiments, the amino acid sequence of the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of the catalytic domain of SEQ ID NO: 112.
[0142] In some embodiments, the catalytic domain is derived from a deubiquitinase that comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 1-112. In some embodiments, the catalytic domain is derived from a deubiquitinase that consists of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 1-112.
[0143] In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:2. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 3. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 4. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 5. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 6.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 7. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:8. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 9. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 10. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 11. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 13. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 14. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 15. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 16. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 17. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 19. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:20. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 21. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 22. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 23. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 24.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 25. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 26. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 27. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 28. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 29. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 30.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 31. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 32. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 33. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 34. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 35. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 36. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 37. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 38. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 39.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 40. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 41. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 42. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 43. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 44. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 45.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 46. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 47. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 48. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 49. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 50. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 51.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 52. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 53. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 54. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 55. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 56. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 57.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 58. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 59. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 60. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 61. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 62. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 63.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 64. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 65. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:66. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 67. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 68. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 69. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 70. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 71. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 72.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 73. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 74. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 75. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 76. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 77. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 78.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 79. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 80. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 81. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 82. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 83. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 84.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 85. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 86. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 87. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 88. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 89. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:90.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 91. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 92. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 93. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 94. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 95. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 96.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 97. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:98. In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:99. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 100. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 101. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 102. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 103. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 104. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 105.In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 106. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 107. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 108. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 109. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 110. In some embodiments, the catalytic domain is derived from a deubiquitinase consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 111.In some embodiments, the catalytic domain is derived from a deubiquitinating enzyme consisting of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:112.
[0144] In some embodiments, the catalytic domain comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 113-220 or 423. In some embodiments, the catalytic domain consists of an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 113-220.
[0145] In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 113. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 114. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 115. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 116. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 117. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:119.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 120. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 121. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 122. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 123. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 124. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 125. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:126.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 127. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 128. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 129. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 130. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 131. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 132. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 133.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 134. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 135. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 136. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 137. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 138. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 139. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:140.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 141. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 142. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 143. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 144. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 145. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 146. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 147.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:148. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 149. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 150. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 151. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 152. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 153. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 154. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 155.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 156. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 157. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 158. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 159. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 160. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 161. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 162.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 163. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 164. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 165. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 166. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 167. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 168. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 169.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 170. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 171. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 172. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 173. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 174. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 175. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 176.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 177. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 178. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 179. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 180. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 181. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 182. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 183.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 184. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 185. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 186. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 187. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 188. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 189. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 190. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 191. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 192.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 193. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 194. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 195. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 196. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 197. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 198. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:199.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 200. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 201. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 202. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 203. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 204. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 205. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:206.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 207. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 208. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 209. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 210. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 211. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:213.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 214. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 215. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 216. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 217. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 219. In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:220.In some embodiments, the catalytic domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:423.
[0146] Table 1 below lists exemplary human deubiquitinating enzymes and the amino acid sequences of exemplary catalytic domains of exemplary human deubiquitinating enzymes. The catalytic domains are exemplary. One of skill in the art could readily determine the amino acid sequence (e.g., catalytic domain) of a human deubiquitinating enzyme sufficient to mediate deubiquitination. Any human deubiquitinating enzyme (functional fragment or variant thereof) can be used to derive a catalytic domain for use in the fusion proteins described herein.
[0147] [Table 1-1]
[0148] [Table 1-2]
[0149] [Table 1-3]
[0150] [Table 1-4]
[0151] [Table 1-5]
[0152] [Table 1-6]
[0153] Table 1-7
[0154] Table 1-8
[0155] Table 1-9
[0156] Table 1-10
[0157] Table 1-11
[0158] Table 1-12
[0159] Table 1-13
[0160] Table 1-14
[0161] Table 1-15
[0162] Table 1-16
[0163] Table 1-17
[0164] Table 1-18
[0165] Table 1-19
[0166] Table 1-20
[0167] Table 1-21
[0168] Table 1-22
[0169] Table 1-23
[0170] Table 1-24
[0171] Table 1-25
[0172] Table 1-26
[0173] Table 1-27
[0174] Table 1-28
[0175] Table 1-29
[0176] Table 1-30
[0177] Table 1-31
[0178] Table 1-32
[0179] Table 1-33
[0180] Table 1-34
[0181] Table 1-35
[0182] Table 1-36
[0183] Table 1-37
[0184] Table 1-38
[0185] Table 1-39
[0186] Table 1-40
[0187] Table 1-41
[0188] Table 1-42
[0189] Table 1-43
[0190] Table 1-44
[0191] Table 1-45
[0192] Table 1-46
[0193] Table 1-47
[0194] Table 1-48
[0195] Table 1-49
[0196] Table 1-50
[0197] Table 1-51
[0198] Table 1-52
[0199] Table 1-53
[0200] Table 1-54
[0201] Table 1-55
[0202] Table 1-56
[0203] Table 1-57
[0204] Table 1-58
[0205] Table 1-59
[0206] Table 1-60
[0207] Table 1-61
[0208] Table 1-62
[0209] Table 1-63
[0210] Table 1-64
[0211] Table 1-65
[0212] Table 1-66
[0213] Table 1-67
[0214] [Table 1-68]
[0215] [Table 1-69]
[0216] [Table 1-70]
[0217] [Table 1-71]
[0218] [Table 1-72]
[0219] 5.3.2 Targeting Domains In some embodiments, the targeting domain comprises a targeting moiety that specifically binds to a target nuclear protein. In some embodiments, the targeting moiety comprises an antibody (or an antigen-binding fragment thereof). In some embodiments, the antibody is a full-length antibody, a single-chain variable fragment (scFv), (scFv)2, scFv-Fc, Fab, Fab', (Fab')2, F(v), a single-domain antibody, a single-chain antibody, a VHH, or a (VHH)2. In some embodiments, the targeting moiety comprises a VHH. In some embodiments, the targeting moiety comprises a (VHH)2.
[0220] In some embodiments, the targeting moiety specifically binds to a wild-type target nuclear protein. In some embodiments, the targeting moiety specifically binds to a wild-type target nuclear protein but not to a variant of the target nuclear protein associated with a genetic disease. In some embodiments, the targeting moiety specifically binds to a naturally occurring variant of the target nuclear protein. In some embodiments, the targeting moiety specifically binds to a naturally occurring variant of the target nuclear protein associated with a genetic disease (e.g., a genetic disease described herein). In some embodiments, the targeting moiety specifically binds to a naturally occurring variant of the target nuclear protein that is the cause of a genetic disease (e.g., a genetic disease described herein). In some embodiments, the targeting moiety specifically binds to a naturally occurring variant of the target nuclear protein that is a loss-of-function variant. In some embodiments, the targeting moiety specifically binds to a naturally occurring variant of the target nuclear protein that is a loss-of-function variant associated with a genetic disease (e.g., a genetic disease described herein). In some embodiments, the targeting moiety specifically binds to a naturally occurring variant of the target nuclear protein that is a loss-of-function variant that causes a genetic disease (e.g., a genetic disease described herein).
[0221] 5.3.2.1 Exemplary Target Nuclear Proteins In some embodiments, the targeting moiety specifically binds to a target nuclear protein (eg, a nuclear protein described herein). Exemplary target nuclear proteins include chromodomain-helicase-DNA binding protein 2 (CHD2), arginine-glutamic acid dipeptide repeat protein (RERE), cyclin-dependent kinase-like 5 (CDKL5), methyl-CpG-binding protein 2 (MECP2), histone-lysine N-methyltransferase 2D (KMT2D), histone-lysine N-methyltransferase SETD5 (SETD5), zinc finger E-box-binding homeobox 2 (ZEB2), and calmodulin-binding transcription activator 1 (CAMTA1), regulator of synaptic function FMR1 (FMR1), pre-mRNA-processing-splicing factor 8 (PRPF8), retinoic acid-inducible protein 1 (RAI1), CREB-binding protein (CREBBP), neurofibromin 1 (NF1), histone-lysine N-methyltransferase 2A (KMT2A), chromodomain-helicase-DNA binding Targeted nuclear proteins include, but are not limited to, histone acetyltransferase 4 (CHD4), H3 lysine-36-specific histone-lysine N-methyltransferase (NSD1), RNA polymerase II transcription mediator subunit 13-like (MED13L), chromosome structural maintenance protein 1A (SMC1A), high-potency global transcriptional activator SNF2L2 (SMARCA2), AT-rich interacting domain-containing protein 1B (ARID1B), pogo transposable element with ZNF domain (POGZ), histone acetyltransferase KAT6B (KAT6B), AT-hook DNA-binding motif-containing protein 1 (AHDC1), histone acetyltransferase p300 (EP300), IQ motif and SEC7 domain-containing protein 2 (IQSEC2), transcription factor 20 (TCF20), putative Polycomb group protein ASXL3 (ASXL3), and histone acetyltransferase KAT6A (KAT6A). In some embodiments, the target nuclear protein is CHD2. In some embodiments, the target nuclear protein is RERE. In some embodiments, the target nuclear protein is CDKL5.In some embodiments, the target nuclear protein is MECP2. In some embodiments, the target nuclear protein is KMT2D. In some embodiments, the target nuclear protein is SETD5. In some embodiments, the target nuclear protein is ZEB2. In some embodiments, the target nuclear protein is CAMTA1. In some embodiments, the target nuclear protein is FMR1. In some embodiments, the target nuclear protein is PRPF8. In some embodiments, the target nuclear protein is RAI1. In some embodiments, the target nuclear protein is CREBBP. In some embodiments, the target nuclear protein is NF1. In some embodiments, the target nuclear protein is KMT2A. In some embodiments, the target nuclear protein is CHD4. In some embodiments, the target nuclear protein is NSD1. In some embodiments, the target nuclear protein is MED13L. In some embodiments, the target nuclear protein is SMC1A. In some embodiments, the target nuclear protein is SMARCA2. In some embodiments, the target nuclear protein is ARID1B. In some embodiments, the target nuclear protein is POGZ. In some embodiments, the target nuclear protein is KAT6B. In some embodiments, the target nuclear protein is AHDC1. In some embodiments, the target nuclear protein is EP300. In some embodiments, the target nuclear protein is IQSEC2. In some embodiments, the target nuclear protein is TCF20. In some embodiments, the target nuclear protein is ASXL3. In some embodiments, the target nuclear protein is KAT6A.
[0222] In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 221. In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 222. In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 223. In some embodiments, the target nucleoprotein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 224. In some embodiments, the target nucleoprotein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 225. In some embodiments, the target nucleoprotein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 226. In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 227. In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 228. In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 229. In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:230.In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 231. In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 232. In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 233. In some embodiments, the target nuclear protein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 234. In some embodiments, the target nuclear protein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 235. In some embodiments, the target nuclear protein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 236. In some embodiments, the target nuclear protein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 237. In some embodiments, the target nuclear protein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 238. In some embodiments, the target nuclear protein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 239. In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:240.In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 241. In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 242. In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 243. In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 244. In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 245. In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 246. In some embodiments, the target nucleoprotein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 247. In some embodiments, the target nucleoprotein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 248. In some embodiments, the target nucleoprotein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 424. In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:425.In some embodiments, the target nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:426.
[0223] Table 2 below provides the wild-type amino acid sequences of exemplary proteins to target for deubiquitination using the fusion proteins described herein.
[0224] [Table 2-1]
[0225] [Table 2-2]
[0226] [Table 2-3]
[0227] [Table 2-4]
[0228] [Table 2-5]
[0229] [Table 2-6]
[0230] [Table 2-7]
[0231] [Table 2-8]
[0232] Table 2-9
[0233] Table 2-10
[0234] Table 2-11
[0235] Table 2-12
[0236] Table 2-13
[0237] Table 2-14
[0238] Table 2-15
[0239] Table 2-16
[0240] Table 2-17
[0241] Table 2-18
[0242] Table 2-19
[0243] Table 2-20
[0244] Table 2-21
[0245] Table 2-22
[0246] Table 2-23
[0247] Table 2-24
[0248] Table 2-25
[0249] Table 2-26
[0250] Table 2-27
[0251] Table 2-28
[0252] [Table 2-29]
[0253] [Table 2-30]
[0254] [Table 2-31]
[0255] [Table 2-32]
[0256] [Table 2-33]
[0257] 5.3.3 Nuclear localization signals In some embodiments, the fusion protein comprises a nuclear localization signal (NLS) at the N-terminus of the fusion protein. Exemplary NLSs are provided in Table 3. In some embodiments, the NLS comprises an amino acid sequence at least 95%, 96%, 97%, 98%, 99%, or 100% identical to one of SEQ ID NOs:249-367.
[0258] [Table 3-1]
[0259] [Table 3-2]
[0260] [Table 3-3]
[0261] 5.3.4 Orientation and Linkers In some embodiments, the effector domain is at the N-terminus of the targeting domain in the fusion protein. In some embodiments, the targeting domain is at the N-terminus of the effector domain in the fusion protein. In some embodiments, the effector domain is operably connected (directly or indirectly) to the C-terminus of the targeting domain. In some embodiments, the effector domain is operably connected (directly or indirectly) to the N-terminus of the targeting domain. In some embodiments, the effector domain is operably connected directly to the C-terminus of the targeting domain. In some embodiments, the effector domain is operably connected directly to the N-terminus of the targeting domain.
[0262] In some embodiments, the effector domain is indirectly operably connected to the C-terminus of the targeting domain.In some embodiments, the effector domain is indirectly operably connected to the N-terminus of the targeting domain.For example, one or more amino acid sequences comprising a linker or encoding one or more polypeptides can be located between the effector moiety and the targeting moiety.In some embodiments, the effector domain is indirectly operably connected to the C-terminus of the targeting domain via a peptide linker.In some embodiments, the effector domain is indirectly operably connected to the N-terminus of the targeting domain via a peptide linker.
[0263] Each component of the fusion proteins described herein may be directly linked to the other or indirectly linked to the other via a peptide linker. Any suitable peptide linker known in the art that enables the effector domain and targeting domain to bind to their respective antigens can be used. In some embodiments, the linker is one or any combination of a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, or a non-helical linker. In some embodiments, the linker is a peptide linker. In some embodiments, the linker is a peptide linker containing glycine or serine, or both glycine and serine amino acid residues. In some embodiments, the peptide linker contains approximately 1-20, 1-15, 1-10, 1-5, 5-20, 5-15, 5-10, or 15-20 amino acids. In some embodiments, the peptide linker comprises 2-25, 5-25, 10-25, 15-25, 20-25, 2-20, 5-20, 10-20, 15-20, 2-15, 5-15, 10-15, 2-10, or 5-10 amino acids, or about 2-25, 5-25, 10-25, 15-25, 20-25, 2-20, 5-20, 10-20, 15-20, 2-15, 5-15, 10-15, 2-10, or 5-10 amino acids. In some embodiments, the linker is a peptide linker consisting of glycine or serine, or both glycine and serine amino acid residues. In some embodiments, the peptide linker consists of 2-25, 5-25, 10-25, 15-25, 20-25, 2-20, 5-20, 10-20, 15-20, 2-15, 5-15, 10-15, 2-10, or 5-10 amino acids, or about 2-25, 5-25, 10-25, 15-25, 20-25, 2-20, 5-20, 10-20, 15-20, 2-15, 5-15, 10-15, 2-10, or 5-10 amino acids.In some embodiments, the peptide linker comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid residues. In some embodiments, the linker is at least 11 amino acids in length. In some embodiments, the linker is at least 15 amino acids in length. In some embodiments, the linker is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid residues in length.
[0264] In some embodiments, the linker is a glycine / serine linker, e.g., a peptide linker consisting essentially of the amino acids glycine and serine, hi some embodiments, the linker is a glycine / serine / proline linker, e.g., a peptide linker consisting essentially of the amino acids glycine, serine, and proline.
[0265] In some embodiments, the amino acid sequence of the linker comprises the amino acid sequence of any one of SEQ ID NOs: 249-367 or 427-436, or the amino acid sequence of any one of SEQ ID NOs: 249-367 or 427-436 with one, two, or three amino acid modifications (e.g., substitutions, deletions, or additions). In some embodiments, the amino acid sequence of the linker consists of the amino acid sequence of any one of SEQ ID NOs: 249-367 or 427-436, or the amino acid sequence of any one of SEQ ID NOs: 249-367 or 427-436 with one, two, or three amino acid modifications (e.g., substitutions, deletions, or additions).
[0266] In some embodiments, the amino acid sequence of the linker comprises the amino acid sequence of any one of SEQ ID NOs: 427-436, or the amino acid sequence of any one of SEQ ID NOs: 427-436 with one, two, or three amino acid modifications (e.g., substitutions, deletions, or additions). In some embodiments, the amino acid sequence of the linker consists of the amino acid sequence of any one of SEQ ID NOs: 427-436, or the amino acid sequence of any one of SEQ ID NOs: 427-436 with one, two, or three amino acid modifications (e.g., substitutions, deletions, or additions).
[0267] The amino acid sequences of exemplary linkers for use in any one or more of the fusion proteins described herein are provided in Table 4 below.
[0268] [Table 4-1]
[0269] [Table 4-2]
[0270] [Table 4-3]
[0271] 5.3.4.1 Conditional Constructs Also described herein are constructs comprising a targeting domain (e.g., VHH, (VHH)2) linked to an effector domain (e.g., an effector domain comprising a catalytic domain of a deubiquitinase, or an effector domain comprising a deubiquitinase). In some embodiments, the linkage between the targeting domain and the effector domain is mediated by binding between a first agent (e.g., a small molecule, protein, or peptide) associated with the targeting domain and a second agent (e.g., a small molecule, protein, or peptide) associated with the effector domain. For example, in one embodiment, the targeting domain may be linked to a first agent that specifically binds to the second agent associated with the effector domain. In some embodiments, the specific binding of the first agent to the second agent is mediated by the addition of a third agent (e.g., a small molecule).
[0272] For example, conditional constructs including KBP / FRB-based dimerization switches, such as those described in, for example, U.S. Patent Application Publication No. 2017 / 0081411 (the entire contents of which are incorporated herein by reference), can be utilized herein. FKBP12 (FKBP or FK506-binding protein) is an abundant cytoplasmic protein that serves as the primary intracellular target for the natural product immunosuppressant, rapamycin. Rapamycin binds to FKBP and the large PI3K homolog FRAP (RAFT, mTOR), thereby acting to dimerize these molecules. In some embodiments, FKBP / FRAP-based switches, also referred to herein as FKBP / FRB-based switches, can utilize heterodimerization molecules, such as rapamycin or rapamycin analogs. FRB is a 93-amino acid portion of FRAP sufficient to bind to the FKBP-rapamycin complex (Chen, J., Zheng, XF, Brown, EJ & Schreiber, SL (1995) Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci USA 92: 4947-51, the entire contents of which are incorporated herein by reference). For example, the targeting domain can bind to FKBP, and the effector domain can bind to FRB. Thus, the link between the targeting domain and the effector domain is mediated by rapamycin and occurs only in the presence of rapamycin.
[0273] Exemplary conditional activation systems that can be used herein include those described in U.S. Patent Application Publication No. 2017 / 0081411; Lajoie MJ, et al. Designed protein logic to target cells with precise combinations of surface antigens. Science. 2020 Sep 25;369(6511):1637-1643. doi: 10.1126 / science.aba6527. Epub 2020 Aug 20. PMID: 32820060; Farrants H, et al. Chemogenetic Control of Nanobodies. Nat Methods. 2020 Mar;17(3):279-282. doi: 10.1038 / s41592-020-0746-7. Epub 2020 Feb 17. PMID: 32066961; and those described in U.S. Patent Application Publication No. 2017 / 0081411.
[0274] 5.3.5 Exemplary Fusion Proteins Exemplary fusion proteins of the present disclosure include, but are not limited to, the following: In one embodiment, the fusion protein comprises an effector domain comprising the catalytic domain of a cysteine protease deubiquitinase, or a functional fragment or variant thereof; and a targeting domain comprising a targeting moiety that specifically binds to a nuclear protein, wherein the nuclear protein is CHD2, RERE, CDKL5, MECP2, KMT2D, SETD5, ZEB2, CAMTA1, FMR1, PRPF8, RAI1, CREBBP, NF1, KMT2A, CHD4, NSD1, MED13L, SMC1A, SMARCA2, ARID1B, POGZ, KAT6B, AHDC1, EP300, IQSEC2, TCF20, ASXL3, KAT6A, SNRPG, LSM2, or NUPR2.
[0275] In one embodiment, the fusion protein comprises an effector domain comprising the catalytic domain of a metalloprotease deubiquitinase, or a functional fragment or functional variant thereof; and a targeting domain comprising a targeting moiety that specifically binds to a nuclear protein, wherein the nuclear protein is CHD2, RERE, CDKL5, MECP2, KMT2D, SETD5, ZEB2, CAMTA1, FMR1, PRPF8, RAI1, CREBBP, NF1, KMT2A, CHD4, NSD1, MED13L, SMC1A, SMARCA2, ARID1B, POGZ, KAT6B, AHDC1, EP300, IQSEC2, TCF20, ASXL3, KAT6A, SNRPG, LSM2, or NUPR2.
[0276] In one embodiment, the fusion protein comprises an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof, wherein the deubiquitinase is a ubiquitin-specific protease (USP), a ubiquitin C-terminal hydrolase (UCH), a Machado-Josephine domain protease (MJD), an ovarian tumor protease (OTU), a MINDY protease, or a ZUFSP protease; and a targeting domain that specifically binds to a nuclear protein. a targeting domain comprising a portion, wherein the nuclear protein is CHD2, RERE, CDKL5, MECP2, KMT2D, SETD5, ZEB2, CAMTA1, FMR1, PRPF8, RAI1, CREBBP, NF1, KMT2A, CHD4, NSD1, MED13L, SMC1A, SMARCA2, ARID1B, POGZ, KAT6B, AHDC1, EP300, IQSEC2, TCF20, ASXL3, KAT6A, SNRPG, LSM2, or NUPR2.
[0277] In one embodiment, the fusion protein comprises an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof, wherein the deubiquitinase is selected from the group consisting of USP1, USP2, USP3, USP4, USP5, USP6, USP7, USP8, USP9X, USP9Y, USP10, USP11, USP12, USP13, USP14, USP15, USP16, USP17, USP17L2, USP18, USP19, USP20, USP21, USP22, USP23, USP24, USP25, USP26, USP27, USP28, USP29, USP2A, USP2B, USP2C, USP2D, USP2E, USP2F, USP2G, USP2H, USP2H, USP2H, USP2H, USP2H, USP2H, USP2H, USP2H, USP2H, USP2H, USP2H, USP2H, USP2H, USP2L, USP2L, USP2L, USP2L, USP2L, USP2L, USP2L, USP2L, USP2L, USP2L, USP2R ...R, USP2L, USP2R, USP2L, USP2R, USP2L, USP2R , USP17L3, USP17L4, USP17L5, USP17L7, USP17L8, USP18, USP19, USP20, USP21, USP22, USP23, USP24, USP25, USP26, U SP27X, USP28, USP29, USP30, USP31, USP32, USP33, USP34, USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42, U an effector domain selected from the group consisting of SP43, USP44, USP45, USP46, BAP1, UCHL1, UCHL3, UCHL5, ATXN3, ATXN3L, OTUB1, OTUB2, MINDY1, MINDY2, MINDY3, MINDY4, or ZUP1; and a targeting domain comprising a targeting moiety that specifically binds to a nuclear protein, wherein the nuclear protein is selected from the group consisting of CHD2, RERE, and a targeting domain that is CDKL5, MECP2, KMT2D, SETD5, ZEB2, CAMTA1, FMR1, PRPF8, RAI1, CREBBP, NF1, KMT2A, CHD4, NSD1, MED13L, SMC1A, SMARCA2, ARID1B, POGZ, KAT6B, AHDC1, EP300, IQSEC2, TCF20, ASXL3, KAT6A, SNRPG, LSM2, or NUPR2.
[0278] In one embodiment, the fusion protein comprises an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof, where the deubiquitinase is listed in Table 1; and a targeting domain comprising a targeting moiety that specifically binds to a nuclear protein, where the selected nuclear protein is CHD2, RERE, CDKL5, MECP2, KMT2D, SETD5, ZEB2, CAMTA1, FMR1, PRPF8, RAI1, CREBBP, NF1, KMT2A, CHD4, NSD1, MED13L, SMC1A, SMARCA2, ARID1B, POGZ, KAT6B, AHDC1, EP300, IQSEC2, TCF20, ASXL3, KAT6A, SNRPG, LSM2, or NUPR2.
[0279] In one embodiment, the fusion protein comprises an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof, wherein the catalytic domain is described in Table 1; and a targeting domain comprising a targeting moiety that specifically binds to a nuclear protein, wherein the nuclear protein is CHD2, RERE, CDKL5, MECP2, KMT2D, SETD5, ZEB2, CAMTA1, FMR1, PRPF8, RAI1, CREBBP, NF1, KMT2A, CHD4, NSD1, MED13L, SMC1A, SMARCA2, ARID1B, POGZ, KAT6B, AHDC1, EP300, IQSEC2, TCF20, ASXL3, KAT6A, SNRPG, LSM2, or NUPR2.
[0280] In one embodiment, the fusion protein comprises an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof, wherein the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 1-112; and a target that specifically binds to a nuclear protein. a targeting domain comprising a targeting moiety, wherein the nuclear protein is CHD2, RERE, CDKL5, MECP2, KMT2D, SETD5, ZEB2, CAMTA1, FMR1, PRPF8, RAI1, CREBBP, NF1, KMT2A, CHD4, NSD1, MED13L, SMC1A, SMARCA2, ARID1B, POGZ, KAT6B, AHDC1, EP300, IQSEC2, TCF20, ASXL3, KAT6A, SNRPG, LSM2, or NUPR2.
[0281] In one embodiment, the fusion protein comprises an effector domain comprising a catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof, wherein the catalytic domain comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 113-220 or 423; and an effector domain that specifically binds to a nuclear protein. and a targeting domain comprising a targeting moiety comprising: a targeting moiety selected from the group consisting of CHD2, RERE, CDKL5, MECP2, KMT2D, SETD5, ZEB2, CAMTA1, FMR1, PRPF8, RAI1, CREBBP, NF1, KMT2A, CHD4, NSD1, MED13L, SMC1A, SMARCA2, ARID1B, POGZ, KAT6B, AHDC1, EP300, IQSEC2, TCF20, ASXL3, KAT6A, SNRPG, LSM2, or NUPR2.
[0282] In one embodiment, the fusion protein comprises an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof, wherein the deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 1-112; and a targeting domain comprising a targeting moiety that specifically binds to a nucleoprotein, wherein the nucleoprotein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 221-248.
[0283] In one embodiment, the fusion protein comprises an effector domain comprising the catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof, wherein the catalytic domain comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 113-220 or 423; and a targeting domain comprising a targeting moiety that specifically binds to a nucleoprotein, wherein the nucleoprotein comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 221-248.
[0284] 5.3.5.1 Further Exemplary Embodiments Further exemplary embodiments of the fusion proteins described herein, which should not be construed as limiting, are provided below.
[0285] Embodiment 1. (a) A fusion protein comprising: an effector moiety comprising a functional fragment of a human deubiquitinase capable of mediating deubiquitination, wherein the human deubiquitinase comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 1 to 112; and a targeting moiety comprising a VHH, (VHH)2, or scFv that specifically binds to a nuclear protein.
[0286] Embodiment 2. A fusion protein comprising: an effector moiety comprising a functional fragment of a human deubiquitinase capable of mediating deubiquitination, the functional fragment comprising an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 113-220 or 423; and a targeting moiety comprising a VHH, (VHH)2, or scFv that specifically binds to a nuclear protein.
[0287] Embodiment 3. A fusion protein comprising an effector moiety comprising a functional fragment of a human deubiquitinase capable of mediating deubiquitination, the functional fragment comprising an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 423, and a targeting moiety comprising a VHH, (VHH)2, or scFv that specifically binds to a nuclear protein.
[0288] Embodiment 4. 4. The fusion protein of any one of embodiments 1 to 3, wherein the targeting moiety is a VHH or (VHH)2.
[0289] Embodiment 5.5. The fusion protein of any one of embodiments 1-4, wherein the nuclear protein is CHD2, RERE, CDKL5, MECP2, KMT2D, SETD5, ZEB2, CAMTA1, FMR1, PRPF8, RAI1, CREBBP, NF1, KMT2A, CHD4, NSD1, MED13L, SMC1A, SMARCA2, ARID1B, POGZ, KAT6B, AHDC1, EP300, IQSEC2, TCF20, ASXL3, KAT6A, SNRPG, LSM2, or NUPR2.
[0290] Embodiment 6. 6. The fusion protein of any one of embodiments 1 to 5, wherein the nuclear protein is CHD2, RERE, CDKL5, MECP2, KMT2D, SETD5, ZEB2, CAMTA1, FMR1, PRPF8, RAI1, CREBBP, NF1, KMT2A, CHD4, NSD1, MED13L, SMC1A, SMARCA2, ARID1B, POGZ, KAT6B, AHDC1, EP300, IQSEC2, TCF20, ASXL3, or KAT6A.
[0291] Embodiment 7. 7. The fusion protein of any one of embodiments 1 to 6, wherein said nuclear protein is SNRPG, LSM2, or NUPR2.
[0292] 5.3.6 Methods for Producing Fusion Proteins The fusion proteins described herein can be produced by any conventional technique known in the art, such as recombinant technology or chemical synthesis (e.g., solid-phase peptide synthesis). In some embodiments, the fusion protein is produced by recombinant expression in a cell (e.g., a eukaryotic cell, e.g., a mammalian cell). Briefly, the fusion protein can be produced by synthesizing DNA encoding the fusion protein and cloning the DNA into any appropriate expression vector. Numerous cloning vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of preference. The gene can be placed under the control of a promoter, a ribosome binding site (for bacterial expression), and optionally an operator and / or one or more enhancer elements, such that the DNA sequence encoding the fusion protein is transcribed into RNA in a host cell transformed with a vector containing the expression construct. The coding sequence may or may not contain a signal peptide or leader sequence. A heterologous leader sequence can be added to the coding sequence to cause secretion of the expressed polypeptide from the host organism. Other regulatory sequences that allow for regulation of the expression of the protein sequence relative to the growth of the host cell may also be desirable. Such regulatory sequences are known to those skilled in the art, and examples include those that turn on and off gene expression in response to chemical or physical stimuli, including the presence of regulatory compounds.Other types of regulatory elements can also be present in vectors, such as enhancer sequences.Regulatory sequences and other regulatory sequences may be ligated to coding sequences before being inserted into vectors, such as the above-mentioned cloning vectors.Alternatively, coding sequences can be directly cloned into expression vectors that already contain regulatory sequences and suitable restriction sites.
[0293] The expression vector can then be used to transform an appropriate host cell. Several mammalian cell lines are known in the art, including immortalized cell lines available from the American Type Culture Collection (ATCC), such as, but not limited to, Chinese hamster ovary (CHO) cells, CHO-suspension cells (CHO-S), HeLa cells, HEK293, baby hamster kidney (BHK) cells, monkey kidney cells (COS), VERO, HepG2, Madin-Darby bovine kidney (MDBK) cells, NOS, U2OS, A549, HT1080, CAD, P19, NIH3T3, L929, N2a, MCF-7, Y79, SO-Rb50, DUKX-X11, and J558L.
[0294] Depending on the selected expression system and host, the fusion protein is produced by growing host cells transformed with the expression vector under conditions in which the fusion protein is expressed. The fusion protein is then isolated and purified from the host cells. If the expression system secretes the fusion protein into the growth medium, the fusion protein can be purified directly from the medium. If the fusion protein is not secreted, it is isolated from cell lysates. The selection of appropriate growth conditions and recovery methods is within the skill of those skilled in the art. After purification, the amino acid sequence of the fusion protein can be determined by repeated cycles of Edman degradation followed by amino acid analysis by HPLC. Other amino acid sequencing methods are also known in the art. After purification, the functionality of the fusion protein can be evaluated, for example, using a bifunctional ELISA, as described herein.
[0295] As described above, the functionality of the fusion protein can be tested by any method known in the art. Each functionality can be measured in a separate assay. For example, the binding of the targeting domain to the target protein can be measured using an enzyme-linked immunosorbent assay (ELISA). The catalytic activity of the effector domain can be measured using any standard deubiquitinase activity assay known in the art, such as the BioVision Deubiquitinase Activity Assay Kit (Fluorometric) Catalog No. K485-100, according to the manufacturer's instructions. The deubiquitinase activity of the fusion proteins described herein can be measured, for example, by using a fluorescent deubiquitinase substrate to detect deubiquitinase activity when the fluorescent substrate is cleaved. Deubiquitinase activity can also be measured using the materials and methods shown in the Examples provided herein.
[0296] 5.4 Nucleic Acids, Host Cells, Vectors, and Viral Particles In one aspect, the present specification provides a nucleic acid molecule encoding the fusion protein described herein.In some embodiments, the nucleic acid molecule is a DNA molecule.In some embodiments, the nucleic acid molecule is an RNA molecule.In some embodiments, the nucleic acid molecule contains at least one modified nucleic acid (e.g., one that increases the stability of the nucleic acid molecule), such as phosphorothioate, N6-methyladenosine (m6A), N6,2'-O-dimethyladenosine (m6Am), 8-oxo-7,8-dihydroguanosine (8-oxoG), pseudouridine (Ψ), 5-methylcytidine (m5C), and N4-acetylcytidine (ac4C).
[0297] In one aspect, provided herein is a host cell (or population of host cells) comprising a nucleic acid encoding a fusion protein described herein. In some embodiments, the nucleic acid is integrated into the genome of the host cell. In some embodiments, the nucleic acid is not integrated into the genome of the host cell. In some embodiments, the nucleic acid is present in an episome of the cell. In some embodiments, the host cell is a human cell. In some embodiments, the host cell is a mammalian cell. In some embodiments, the host cell is a mouse, rat, hamster, guinea pig, cat, dog, or human cell. In some embodiments, the host cell is modified in vitro, ex vivo, or in vivo.
[0298] Nucleic acid can be introduced into host cell by any suitable method known in the art (for example, as described herein).For example, viral delivery system (for example, retrovirus, adenovirus, adeno-associated virus, herpesvirus, lentivirus, poxvirus, vaccinia virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, Epstein-Barr virus, influenza virus, retrovirus, myxoma virus, Maraba virus, rhabdovirus or coxsackie virus delivery system) can be used to deliver the nucleic acid (for example, DNA or RNA molecule) encoding fusion protein for expression in host cell.In some embodiments, the nucleic acid encoding fusion protein is present in episome in host cell.In some embodiments, the nucleic acid encoding fusion protein is integrated into the genome of host cell.In some embodiments, the virus is capable of replication.In some embodiments, the virus is replication-defective.
[0299] In some embodiments, nucleic acids (DNA or RNA) are delivered to host cells using non-viral vectors (e.g., plasmids) encoding fusion proteins. In some embodiments, the nucleic acids encoding fusion proteins are present in episomes within host cells. In some embodiments, the nucleic acids encoding fusion proteins are integrated into the genome of host cells. Exemplary non-viral transfection methods known in the art include, but are not limited to, direct delivery of DNA by ex vivo transfection, injection (e.g., microinjection), electroporation, liposome-mediated transfection, receptor-mediated transfection, particle bombardment, or agitation with silicon carbide fibers. By applying such techniques, nucleic acids encoding the fusion proteins described herein may be stably or transiently transfected into these cells to express the encoded fusion proteins.
[0300] In one aspect, the present specification provides a vector comprising the nucleic acid encoding the fusion protein described herein (for example, the nucleic acid described herein).In some embodiments, the vector is a viral vector.Exemplary viral vectors include but are not limited to retroviral vectors, adenoviral vectors, adeno-associated viral vectors, herpesvirus vectors, lentivirus vectors, poxvirus vectors, vaccinia virus vectors, vesicular stomatitis virus vectors, poliovirus vectors, Newcastle disease virus vectors, Epstein-Barr virus vectors, influenza virus vectors, reovirus vectors, myxoma virus vectors, Maraba virus vectors, rhabdovirus vectors and coxsackievirus vectors.In some embodiments, the vector is a non-viral vector.In some embodiments, the non-viral vector is a plasmid.
[0301] In one aspect, provided herein is a viral particle (or a population of viral particles) comprising a nucleic acid (for example, a nucleic acid described herein) encoding the fusion protein described herein.In some embodiments, the viral particle is an RNA virus.In some embodiments, the viral particle is a DNA virus.In some embodiments, the viral particle comprises a double-stranded genome.In some embodiments, the viral particle comprises a single-stranded genome.Exemplary viral particles include, but are not limited to, retrovirus, adenovirus, adeno-associated virus, herpesvirus, lentivirus, poxvirus, vaccinia virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, Epstein-Barr virus, influenza virus, reovirus, myxoma virus, Maraba virus, rhabdovirus, or coxsackie virus.
[0302] 5.5 Pharmaceutical Compositions In one aspect, provided herein is a pharmaceutical composition comprising: 1) a fusion protein described herein, a nucleic acid encoding a fusion protein described herein, a vector comprising a nucleic acid encoding a fusion protein described herein, or a viral particle comprising a nucleic acid encoding a fusion protein described herein; and 2) at least one pharmaceutically acceptable carrier, excipient, stabilizer, buffer, diluent, surfactant, preservative, and / or adjuvant (see, e.g., Remington's Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, PA). One skilled in the art can select an appropriate excipient for inclusion in the pharmaceutical composition. For example, the formulation of the pharmaceutical composition may vary based on the route of administration (e.g., intravenous, subcutaneous, etc.) and / or the active molecule contained in the pharmaceutical composition (e.g., a viral particle, a non-viral vector, a nucleic acid not contained in a vector).
[0303] Acceptable carriers, excipients, or stabilizers are preferably nontoxic to recipients at the dosages and concentrations employed, and may include buffers such as phosphates, citrates, or other organic acids; antioxidants, including ascorbic acid or methionine; preservatives (e.g., octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl alcohol, or benzyl alcohol; alkyl parabens, such as methyl paraben or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; or m-cresol); low molecular weight (less than about 10 residues) polypeptides; These include proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, or other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as TWEEN®, PLURONICS®, or polyethylene glycol (PEG).
[0304] In one embodiment, the present disclosure provides a pharmaceutical composition comprising the fusion protein described herein for use as a medicament.In another embodiment, the present disclosure provides a pharmaceutical composition for use in a method for treating cancer.In some embodiments, the pharmaceutical composition comprises the fusion protein disclosed herein and optionally one or more additional prophylactic or therapeutic agents in a pharmaceutically acceptable carrier.
[0305] The pharmaceutical composition may be formulated for any route of administration to a subject. Specific examples of routes of administration include parenteral administration (e.g., intravenous, subcutaneous, intramuscular). In some embodiments, the pharmaceutical composition is formulated for intravenous administration. In some embodiments, the pharmaceutical composition is formulated for subcutaneous administration. Injections can be prepared in conventional forms, either as solutions or suspensions. Injections may contain one or more excipients. Exemplary excipients include, for example, water, saline, dextrose, glycerol, or ethanol. In addition, if desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, or other agents, such as, for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, or cyclodextrins.
[0306] In some embodiments, the pharmaceutical composition is formulated for intravenous administration. Suitable carriers for intravenous administration include saline or phosphate buffered saline (PBS), or solutions containing thickening or solubilizing agents such as glucose, polyethylene glycol, or polypropylene glycol, or a mixture thereof.
[0307] Compositions to be used for in vivo administration can be sterile, which is readily accomplished, for example, by filtration through sterile filtration membranes.
[0308] Pharmaceutically acceptable carriers used in the parenteral products described herein include, for example, aqueous media, non-aqueous media, antibacterial agents, isotonicity agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents, or other pharmaceutically acceptable substances. Examples of aqueous media that can be incorporated into one or more of the formulations described herein include sodium chloride injection, Ringer's injection, isotonic dextrose injection, sterile water injection, dextrose or lactated Ringer's injection. Non-aqueous parenteral media that can be incorporated into one or more of the formulations described herein include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil, or peanut oil. Antimicrobial agents in bacteriostatic or fungistatic concentrations can be added to the parenteral products described herein and packaged in multi-dose containers containing phenol or cresol, mercurials, benzyl alcohol, chlorobutanol, p-hydroxybenzoic acid methyl ester and p-hydroxybenzoic acid propyl ester, thimerosal, benzalkonium chloride, or benzethonium chloride. Tonicity agents that can be incorporated into one or more of the formulations described herein include sodium chloride or dextrose. Buffers that can be incorporated into one or more of the formulations described herein include phosphate or citrate. Antioxidants that can be incorporated into one or more of the formulations described herein include sodium bisulfate. Local anesthetics that can be incorporated into one or more of the formulations described herein include procaine hydrochloride. Suspending and dispersing agents that can be incorporated into one or more of the formulations described herein include sodium carboxymethylcellulose, hydroxypropylmethylcellulose, or polyvinylpyrrolidone. An emulsifying agent that can be incorporated into one or more of the formulations described herein includes polysorbate 80 (TWEEN® 80). A sequestering or chelating agent for metal ions that can be incorporated into one or more of the formulations described herein is EDTA.Pharmaceutical carriers that can be incorporated into one or more of the formulations described herein also include ethyl alcohol, polyethylene glycol or propylene glycol for water miscible vehicles; or sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.
[0309] The exact dosage that should be adopted in pharmaceutical compositions also depends on the route of administration and the severity of the condition caused by it, and should be determined by the judgment of the doctor and the situation of each patient.For example, effective dosage can also vary depending on administration means, target site, patient's physiological condition (including age, weight and health), other medicines that are administered, or whether the treatment is preventive or therapeutic.Treatment dosage is preferably set to optimize safety and effectiveness.
[0310] 5.6 Methods of Therapeutic Use In one aspect, provided herein is a method of treating a disease in a subject by administering to a subject having the disease a fusion protein described herein, a nucleic acid encoding a fusion protein described herein, a vector comprising a nucleic acid encoding a fusion protein described herein, or a viral particle comprising a nucleic acid encoding a fusion protein described herein.
[0311] Fusion protein can be delivered to host cell by any method known in the art.For example, viral delivery system (for example, retrovirus, adenovirus, adeno-associated virus, herpesvirus, lentivirus, poxvirus, vaccinia virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, Epstein-Barr virus, influenza virus, reovirus, myxoma virus, Maraba virus, rhabdovirus, enadenotucirev or coxsackie virus) can be used to deliver the nucleic acid (for example, DNA or RNA molecule) encoding fusion protein for expression in target cell population.In some embodiments, the nucleic acid encoding fusion protein is present in episome in target cell population.In some embodiments, the nucleic acid encoding fusion protein is integrated into the genome of target cell population.In some embodiments, the virus is capable of replication.In some embodiments, the virus is replication-deficient.
[0312] In some embodiments, a fusion protein is administered to a subject. In some embodiments, a nucleic acid (DNA or RNA) is administered to a subject. In some embodiments, the nucleic acid (DNA or RNA) is complexed in a carrier (e.g., a nanoparticle, liposome, microsphere). In some embodiments, a nucleic acid (DNA or RNA) in a non-viral vector (e.g., a plasmid) encoding the fusion protein is administered to a subject.
[0313] 5.6.1 Administration Fusion protein can be delivered to host cell by any method known in the art.For example, viral delivery system (for example, retrovirus, adenovirus, adeno-associated virus, herpesvirus, lentivirus, poxvirus, vaccinia virus, vesicular stomatitis virus, poliovirus, Newcastle disease virus, Epstein-Barr virus, influenza virus, reovirus, myxoma virus, Maraba virus, rhabdovirus, enadenotucirev or coxsackie virus) can be used to deliver the nucleic acid (for example, DNA or RNA molecule) that encodes fusion protein for expression in target cell population.In some embodiments, the nucleic acid that encodes fusion protein is present in episome in target cell population.In some embodiments, the nucleic acid that encodes fusion protein is integrated into the genome of target cell population.In some embodiments, the virus can replicate.In some embodiments, the virus is replication-defective.
[0314] In some embodiments, a fusion protein is administered to a subject. In some embodiments, a nucleic acid (DNA or RNA) is administered to a subject. In some embodiments, the nucleic acid (DNA or RNA) is complexed in a carrier (e.g., a nanoparticle, liposome, microsphere). In some embodiments, a nucleic acid (DNA or RNA) in a non-viral vector (e.g., a plasmid) encoding the fusion protein is administered to a subject.
[0315] In some embodiments, the fusion protein is administered parenterally. In some embodiments, the fusion protein is administered via intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, or intrasternal injection or infusion. In some embodiments, the fusion protein is administered intravenously. In some embodiments, the fusion protein is administered subcutaneously. In some embodiments, the fusion protein is administered via a non-parenteral route or orally. Other non-parenteral routes include topical, epidermal, or mucosal administration routes, such as intranasal, intravaginal, rectal, sublingual, or topical. Administration can also be, for example, single, multiple, and / or over one or more extended periods.
[0316] In some embodiments, the methods disclosed herein are used in place of standard treatment methods. In certain embodiments, standard treatment methods are used in combination with any of the methods disclosed herein. In some embodiments, the methods disclosed herein are used after standard treatment methods have failed. In some embodiments, the fusion protein is administered simultaneously with, before, or after an additional therapeutic agent. In some embodiments, the disease is a genetic disease.
[0317] 5.6.2 Exemplary Genetic Disorders In some embodiments, the disease is a genetic disease. In some embodiments, the genetic disease is associated with decreased expression of a functional target nuclear protein. In some embodiments, the genetic disease is associated with decreased stability of a functional target nuclear protein. In some embodiments, the genetic disease is associated with increased ubiquitination of a target nuclear protein. In some embodiments, the genetic disease is associated with increased ubiquitination and degradation of a target nuclear protein. In some embodiments, the genetic disease is a haploinsufficiency disease.
[0318] In some embodiments, the disease is selected from the group consisting of early CHD2 encephalopathy, CDKL5 deficiency disorder, SETD5 syndrome, CAMTA1 syndrome, infantile epileptic encephalopathy (e.g., type 2), childhood-onset epileptic encephalopathy, 1p36 deletion syndrome, Rett syndrome, Kabuki syndrome 1, mental retardation autosomal dominant 23, Mowat-Wilson syndrome, Wiedemann-Steiner syndrome, Schifflim-Hitz-Weiss syndrome, Sotos syndrome, MED13L syndrome, SMC1A syndrome, Nicolaides-Baraitser syndrome, ARID1B-related disorder, White-Sutton syndrome, KAT6B disorder, Shea-Gibbs syndrome, Menke-Hennekam syndrome 2, IQSEC2-related disorder, TCF20-related disorder, Bainbridge-Lopers syndrome, and KATA6 syndrome.
[0319] In some embodiments, the target nuclear protein is CHD2 and the disease is childhood-onset epileptic encephalopathy. In some embodiments, the target nuclear protein is CHD2 and the disease is CHD2 encephalopathy. In some embodiments, the target nuclear protein is RERE and the disease is 1p36 deletion syndrome. In some embodiments, the target nuclear protein is CDKL5 and the disease is early infantile epileptic encephalopathy (e.g., type 2). In some embodiments, the target nuclear protein is CDKL5 and the disease is CDKL5 deficiency disorder. In some embodiments, the target nuclear protein is MECP2 and the disease is Rett syndrome. In some embodiments, the target nuclear protein is KMT2D and the disease is Kabuki syndrome 1. In some embodiments, the target nuclear protein is SETD5 and the disease is mental retardation autosomal dominant 23. In some embodiments, the target nuclear protein is ZEB2 and the disease is Mowat-Wilson syndrome. In some embodiments, the target nuclear protein is KMT2A and the disease is Wiedemann-Steiner syndrome. In some embodiments, the target nuclear protein is CHD4 and the disease is Schiflim-Hitz-Weiss syndrome. In some embodiments, the target nuclear protein is NSD1 and the disease is Sotos syndrome. In some embodiments, the target nuclear protein is SMC1A and the disease is SMC1A syndrome. In some embodiments, the target nuclear protein is SMARCA2 and the disease is Nicolaides-Baraitser syndrome. In some embodiments, the target nuclear protein is ARID1B and the disease is an ARID1B-associated disorder. In some embodiments, the target nuclear protein is POGZ and the disease is White-Sutton syndrome. In some embodiments, the target nuclear protein is KAT6B and the disease is a KAT6B disorder. In some embodiments, the target nuclear protein is AHDC1 and the genetic disease is Shea-Gibbs syndrome. In some embodiments, the target nuclear protein is EP300 and the disease is Menke-Hennekam syndrome 2. In some embodiments, the target nuclear protein is IQSEC2 and the disease is an IQSEC2-associated disorder. In some embodiments, the target nuclear protein is TCF20 and the disease is a TCF20-associated disorder.In some embodiments, the target nuclear protein is ASXL3 and the disease is Bainbridge-Lopers syndrome. In some embodiments, the target nuclear protein is KAT6A and the disease is KATA6 syndrome. In some embodiments, the target nuclear protein is MED13L and the disease is MED13L syndrome. In some embodiments, the target nuclear protein is CAMTA1 and the disease is CAMTA1 syndrome. In some embodiments, the target nuclear protein is FMR1 and the disease is Fragile X syndrome. In some embodiments, the target nuclear protein is PRPF8 and the disease is Retinitis Pigmentosa 13. In some embodiments, the target nuclear protein is RAI1 and the disease is Smith-Maginnis syndrome. In some embodiments, the target nuclear protein is CREBBP and the disease is Rubinstein-Taybi syndrome. In some embodiments, the target nuclear protein is NF1 and the disease is Neurofibromatosis (e.g., Type 1).
[0320] 5.7 Kits In one aspect, provided herein are kits for therapeutic use comprising a fusion protein described herein, a nucleic acid encoding a fusion protein described herein, a vector comprising a nucleic acid encoding a fusion protein described herein, or a viral particle comprising a nucleic acid encoding a fusion protein described herein. The kit typically includes a label and instructions indicating the intended use of the contents of the kit. An expiration date label includes any written or recorded material provided on or with the kit, or otherwise accompanying the kit. Thus, the present disclosure provides kits for treating a subject suffering from a disease (e.g., a genetic disease), the kit including: (a) a dosage of a fusion protein, a nucleic acid encoding a fusion protein described herein, a vector comprising a nucleic acid encoding a fusion protein described herein, or a viral particle comprising a nucleic acid encoding a fusion protein described herein; and (b) instructions for using the fusion protein in any of the treatment methods disclosed herein. [Example]
[0321] This invention is further illustrated by the following examples, which should not be construed as further limiting.
[0322] 6.1 [Example 1] Generation of targeted engineered deubiquitinating enzymes This example provides a general experimental method for demonstrating enDUB-associated expression upregulation using a fluorescently tagged target protein together with a fluorophore-tagged engineered deubiquitinating enzyme (enDUB). For illustrative purposes, the constructs disclosed below are synthesized in vectors suitable for mammalian expression. Typically, the target protein is expressed with a C-terminal YFP followed by a P2A cleavage signal and an mCherry protein as a second reporter (target protein-YFP-P2A-mCherry). This construct is co-transfected in the presence of a trifunctional fusion protein (CFP-P2A-anti-YFP nanobody-enDUB) consisting of a CFP protein followed by a P2A signal and an engineered DUB followed by a nanobody that specifically binds to YFP. In therapeutic applications, a targeting nanobody (or other specific binder) is directed against the wild-type (or disease-causing mutant) protein to be upregulated in cells, while the enDUB is fused to a binding protein for the target protein. The target protein binding moiety can be any antibody or antibody fragment, nanobody, or any other non-antibody scaffold, such as fibronectin, anticalin, ankyrin repeat, or natural binding protein, that specifically interacts with the target protein to be upregulated. The amino acid sequences of the components of the tested fusion proteins are provided in Table 5 below.
[0323] [Table 5-1]
[0324] [Table 5-2]
[0325] [Table 5-3]
[0326] The amino acid sequences of the tested fusion proteins are provided in Table 6 below.
[0327] [Table 6-1]
[0328] [Table 6-2]
[0329] [Table 6-3]
[0330] [Table 6-4]
[0331] [Table 6-5]
[0332] [Table 6-6]
[0333] [Table 6-7]
[0334] [Table 6-8]
[0335] [Table 6-9]
[0336] [Table 6-10]
[0337] [Table 6-11]
[0338] 6.2 [Example 2] Testing targeted engineered deubiquitinases To demonstrate upregulation of a target protein in the context of specific targeting enDUBs, the following experiment is performed. Overview of the structures used: Control experiments using non-targeting enDUB fusions 〇 Target-YFP-P2A-mCherry CFP-P2A-enDUB (non-targeting control enDUB) Test constructs for upregulation: 〇 Target-YFP-P2A-mCherry CFP-P2A-α-YFP nanobody-enDUB or a specific targeting enDUB fusion consisting of: CFP-P2A-anti-targeting binder-enDUB
[0339] A plasmid carrying a YFP-tagged target protein is co-transfected into HEK cells with a plasmid carrying an enDUB fused to a target-binding protein. A control construct carrying an enDUB without a targeting binder is also co-transfected with the labeled target protein. 24-48 hours later, transfected cells are analyzed by FACS or by upregulation from the control. The mCherry signal on the target protein is used to normalize for transfection efficiency, while the CFP signal is used to normalize for transfection efficiency of the enDUB construct. The YFP fused to the target protein is a readout for target gene expression, which is plotted against the signal in the control transfection. A relative increase in YFP fluorescence from the control demonstrates upregulation in the presence of enDUB.
[0340] 6.3 [Example 3] Screening Assays for Testing Fusion Proteins The following example describes an assay for analyzing the ability of a targeted engineered deubiquitinase (enDub) (e.g., the enDub described herein) to increase expression of a target protein. Generally, the assay involves tagging the target protein with a fluorescent tag (e.g., NanoLuciferase (NLuc)) and an alpha-tag (α-tag); and tagging a fusion protein of enDub and an anti-alpha tag nanobody with a different fluorescent tag (e.g., firefly luciferase (FLuc)) via a cleavable linker. The use of two different fluorescent tags allows for signal normalization to compensate for variations in transfection / expression, as the second fluorescent tag is rapidly cleaved from the enDub-anti-alpha tag fusion protein intracellularly upon cleavage of the cleavable linker. Figure 2 provides a general schematic of the cellular aspect of the assay. The protocol, including materials and methods, is described below.
[0341] CHO-K1 cells were digested with 0.25% (w / v) trypsin-EDTA at 37°C for 5 minutes. The digestion was stopped by adding complete medium to the CHO-K1 cell culture. The CHO-K1 cells were centrifuged at 800 rpm for 5 minutes. After centrifugation, the supernatant was discarded, and the CHO-K1 cells were resuspended in 2 mL of medium and counted. 6CHO-K1 cells were electroporated at 440V with 0.5 μg of plasmid encoding NLuc- and alpha-tag-tagged target proteins and 1 μg of plasmid encoding a) enDub-anti-alpha tag nanobody-FLuc fusion protein (experimental), b) enDub (control), or anti-alpha tag nanobody (control). 5E+4 cells per well were plated in a 24-well plate and cultured at 37°C and 5% CO for 24 hours. Cells were digested with 0.25% (w / v) trypsin-EDTA at 37°C for 5 minutes. Complete medium was added to the culture to stop the digestion, and cells were counted for use in the NanoGlo® Dual Luciferase® Assay (Promega). This assay allows for the detection of FLuc and NLuc® in a single sample. The NanoGlo® Dual-Luciferase® Assay was performed according to the manufacturer's instructions (Promega, Nano-Glo® Dual-Luciferase® Reporter Assay Technical Manual #TM426). Briefly, 1E+4 cells / well were plated into a 96-well black plate and cultured at 37°C, 5% CO2 for 24 hours. The plate was removed from the incubator and allowed to equilibrate to room temperature. Samples were modified as necessary to have a starting volume of 80 μl / well. 80 μl of ONE-Glo™ EX Reagent was injected into all sample wells and incubated for 3 minutes. Firefly luminescence was read in all sample wells using a 1-second integration time. 80 μl of NanoDLR™ Stop & Glo® Reagent was injected into all sample wells; incubated for 5 minutes. NanoLuc® luminescence was read in all sample wells using a 1-second integration time. The dispense lines were washed and the data analyzed per the manufacturer's instructions (Nano-Glo® Dual-Luciferase® Reporter Assay Technical Manual #TM426.).
[0342] The amino acid sequences of the components of the fusion proteins used in the assay are detailed in Table 7 below.
[0343] [Table 7]
[0344] The amino acid sequences of exemplary target fusion proteins comprising a target protein, NLuc, and an alpha tag are detailed in Table 8 below.
[0345] [Table 8-1]
[0346] [Table 8-2]
[0347] [Table 8-3]
[0348] [Table 8-4]
[0349] The amino acid sequences of exemplary fusion proteins containing control or targeted engineered deubiquitinating enzymes are detailed in Table 9 below.
[0350] [Table 9-1]
[0351] [Table 9-2]
[0352] Assays were performed using the tagged proteins and targeted enDub described in Tables 7 and 8 above. Results for SNRPG targeting, showing a 2.37-fold increase in SNRPG protein expression, are shown in Figure 3. Results for LSM2 targeting, showing a 1.87-fold increase in LSM2 protein expression, are shown in Figure 4. Results for NUPR2 targeting, showing a 1.13-fold increase in NURP2 protein expression, are shown in Figure 5. The control used for the SNRPG, LSM2, and NUPR2 experiments was an engineered deubiquitinase without a nanobody targeting the alpha-tag. Transduction efficiency was normalized using the firefly luciferase signal as a reference and the ratio of the NLuc signal divided by the firefly luciferase signal plotted on the y-axis.
[0353] The present invention should not be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.
[0354] All references (e.g., publications or patents or patent applications) cited herein are incorporated by reference in their entirety for all purposes to the same extent as if each individual reference (e.g., publication or patent or patent application) was specifically and individually indicated to be incorporated by reference in its entirety for all purposes. Other embodiments are within the scope of the following claims.
Claims
1. a. an effector domain comprising a catalytic domain of a deubiquitinase, or a functional fragment or variant thereof, b. A targeting domain that includes a targeting moiety that specifically binds to a nuclear protein. An effector domain operably linked to: A nucleic acid molecule encoding a fusion protein comprising:
2. 2. The nucleic acid molecule of claim 1, wherein the effector domain comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 80, 1-79, or 81-112.
3. 2. The nucleic acid molecule of claim 1, wherein the catalytic domain comprises a catalytic domain derived from a deubiquitinase that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 80, 1-79, or 81-112.
4. 2. The nucleic acid molecule of claim 1, wherein the catalytic domain comprises an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 113-220 or 423.
5. The nucleic acid molecule of claim 1 , wherein the moiety that specifically binds to a nuclear protein comprises an antibody, or a functional fragment or functional variant thereof.
6. The nucleic acid molecule of claim 5 , wherein the antibody, or functional fragment or functional variant thereof, comprises a VHH.
7. The nucleic acid molecule of claim 1 , wherein the nuclear protein is a transcription factor.
8. The nuclear protein is selected from the group consisting of chromodomain-helicase-DNA binding protein 2 (CHD2), arginine-glutamic acid dipeptide repeat protein (RERE), cyclin-dependent kinase-like 5 (CDKL5), methyl-CpG binding protein 2 (MECP2), histone-lysine N-methyltransferase 2D (KMT2D), histone-lysine N-methyltransferase SETD5 (SETD5), zinc finger E-box binding homeobox (ZF) and cytoplasmic endothelial cell line (CTC). Zeb2 (ZEB2), calmodulin-binding transcription activator 1 (CAMTA1), regulator of synaptic function FMR1 (FMR1), pre-mRNA-processing-splicing factor 8 (PRPF8), retinoic acid-inducible protein 1 (RAI1), CREB-binding protein (CREBBP), neurofibromin (NF1), and histone-lysine N-methyltransferase 2A (KMT2A), a chromodomain-helicase-DNA-binding protein 4 (CHD4), H3 lysine-36-specific histone-lysine N-methyltransferase (NSD1), RNA polymerase II transcription mediator subunit 13-like (MED13L), maintenance of chromosome structure protein 1A (SMC1A), high-potency global transcriptional activator SNF2L2 (SMARCA2), AT-rich interacting domain-containing protein 1B (ARID1B), pogo transposable element with ZNF domain (POGZ), histone acetyltransferase KAT6B (KAT6B), AT-hook DNA-binding motif-containing protein 1 (AHDC1), histone acetyltransferase p300 (EP300), IQ motif and SEC7 domain-containing protein 2 (IQSEC2), transcription factor 20 (TCF20), putative polycomb group protein ASXL3 (ASXL3), histone acetyltransferase KAT6A (KAT6A), small nuclear ribonucleoprotein G (SNRPG), U6 The nucleic acid molecule of claim 1 , which is snRNA-associated Sm-like protein LSm2 (LSM2) or nuclear protein 2 (NUPR2).
9. 2. The nucleic acid molecule of claim 1, wherein the nucleoprotein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs:221-248 or 424-426.
10. The nucleic acid molecule of claim 1 , wherein the effector domain is indirectly operably linked to the targeting domain via a peptide linker.
11. The nucleic acid molecule of claim 1 , further encoding a nuclear localization signal (NLS).
12. The nucleic acid molecule of claim 1 which is a DNA molecule or an RNA molecule.
13. A vector comprising the nucleic acid molecule of claim 1.
14. The vector described in claim 13, which is a viral vector.
15. A viral particle comprising the nucleic acid molecule of claim 1.
16. A pharmaceutical composition comprising the nucleic acid molecule of claim 1 and an excipient.
17. A pharmaceutical composition for treating a genetic disease, comprising the nucleic acid molecule described in claim 1.
18. The disease may be CHD2 encephalopathy, CDKL5 deficiency disorder, SETD5 syndrome, CAMTA1 syndrome, early infantile epileptic encephalopathy type 2, childhood-onset epileptic encephalopathy, 1p36 deletion syndrome, Rett syndrome, Kabuki syndrome 1, mental retardation autosomal dominant 23, Mowat-Wilson syndrome, cerebellar ataxia, fragile X syndrome, retinitis pigmentosa 13, Smith-Maginis syndrome, Rubinstein-Taybi syndrome, neurofibromatosis (e.g., type 1), Weide syndrome, 18. The pharmaceutical composition of claim 17, which is Mann-Steiner syndrome, Schifrim-Hitz-Beiss syndrome, Sotos syndrome, MED13L syndrome, SMC1A syndrome, Nicolaides-Baraitser syndrome, ARID1B-related disorder, White-Sutton syndrome, KAT6B disorder, Shea-Gibbs syndrome, Menke-Hennekam syndrome 2, IQSEC2-related disorder, TCF20-related disorder, Bainbridge-Lopers syndrome, or KATA6 syndrome.
19. a. the target nuclear protein is CHD2 and the disease is childhood-onset epileptic encephalopathy; b. the target nuclear protein is CHD2 and the disease is CHD2 encephalopathy; c. the target nuclear protein is RERE and the disease is 1p36 deletion syndrome; d. the target nuclear protein is CDR-KL5 and the disease is early infantile epileptic encephalopathy (e.g., type 2); e. the target nuclear protein is CDKL5 and the disease is a CDKL5 deficiency disorder; f. the target nuclear protein is MECP2 and the disease is Rett Syndrome; g. the target nuclear protein is KMT2D and the disease is Kabuki syndrome 1; h. the target nuclear protein is SETD5 and the disease is mental retardation autosomal dominant 23; i. the target nuclear protein is ZEB2 and the disease is Mowat-Wilson syndrome; j. the target nuclear protein is KMT2A and the disease is Wiedemann-Steiner syndrome; k. the target nuclear protein is CHD4 and the disease is Schifrim-Hitz-Weiss syndrome; l. the target nuclear protein is NSD1 and the disease is Sotos syndrome; m. the target nuclear protein is SMC1A and the disease is SMC1A syndrome; n. the target nuclear protein is SMARCA2 and the disease is Nicolaides-Baraitser syndrome; o. the target nuclear protein is ARID1B and the disease is an ARID1B-associated disorder; p. the target nuclear protein is POGZ and the disease is White-Sutton syndrome; q. the target nuclear protein is KAT6B and the disease is a KAT6B disorder; r. the target nuclear protein is AHDC1 and the genetic disease is Shea-Gibbs syndrome; s. the target nuclear protein is EP300 and the disease is Menke-Hennekam syndrome 2; t. the target nuclear protein is IQSEC2 and the disease is an IQSEC2-associated disorder; u. the target nuclear protein is TCF20 and the disease is a TCF20-associated disorder; v. the target nuclear protein is ASXL3 and the disease is Bainbridge-Lopers syndrome; w. the target nuclear protein is KAT6A and the disease is KATA6 syndrome; x. the target nuclear protein is MED13L and the disease is MED13L syndrome; y. the target nuclear protein is CAMTA1 and the disease is CAMTA1 syndrome; z. the target nuclear protein is FMR1 and the disease is fragile X syndrome; aa. the target nuclear protein is PRPF8 and the disease is retinitis pigmentosa 13; bb. the target nuclear protein is RAI1 and the disease is Smith-Maginis syndrome; cc. the target nuclear protein is CREBBP and the disease is Rubinstein-Taybi syndrome; or dd. The target nuclear protein is NF1 and the disease is neurofibromatosis (e.g., type 1); 18. The pharmaceutical composition of claim 17.
20. The pharmaceutical composition of claim 17, wherein the disease is a haploinsufficiency disease.
21. 18. The pharmaceutical composition of claim 17, wherein the haploinsufficiency disorder is selected from the group consisting of early infantile epileptic encephalopathy type 2, childhood-onset epileptic encephalopathy, 1p36 deletion syndrome, Rett syndrome, mental retardation autosomal dominant 23, Mowat-Wilson syndrome, cerebellar ataxia, Smith-Maginis syndrome, or neurofibromatosis.
